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Abstract
In rare genetic diseases, a single genetic alteration can be enough to cause a severe disor-
der. Recent advances in genetic research have introduced exome or genome sequencing
into clinical care. However, each sequencing run delivers a myriad of candidate variants
that have to be sifted through in the hunt for the causative mutation - a major data
challenge, for which researchers and clinicians have to rely on computer tools.
With MutationDistiller, we have developed a freely available online tool to analyse whole
exome sequencing data in a user-driven fashion. The tool aims at clinicians and re-
searchers without bioinformatic experience who are working with real patient data, and
allows them to distil the most likely causative variants from the sea of candidates. By
uploading the patient’s genetic information and adding information on the symptoms,
they can combine genotype and phenotype to find the culprit. MutationDistiller allows a
wide range of phenotype data, such as HPO, OMIM and Orphanet entries, gene panels,
expression data, Gene Ontology terms, and affected pathways. In the output, the pro-
gram provides an ordered list of candidate alterations matching the user-defined criteria.
In addition, crucial data on the alteration and the affected gene can be reviewed at a
glance.
This thesis describes the program, its background and usage, and compares it to current
state-of-the-art tools. When assessing the tool, we found that it matches or out-competes
similar software and is able to find the causative variant in a majority of cases. Moreover,
its user-friendliness makes it a handy tool for clinicians and researchers, as is reflected
by its usage: MutationDistiller routinely sees over 1,000 cases per month and has been
used in over 14,000 cases at the time of writing. Thus, MutationDistiller has already
found its way into the clinic.
The tool, comprehensive documentation and example cases are freely available at
https://www.mutationdistiller.org/
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Zusammenfassung
Im Fall von monogenen Krankheiten kann eine einzelne schädliche Mutation krankheits-
auslösend sein. Fortschritte in der genetischen Forschung haben dazu beigetragen, dass
Genom- oder Exomsequenzierungen zur Detektion krankheitsverursachender Mutatio-
nen in der Klinik einen Platz gefunden haben. Bei jeder Sequenzierung fallen jedoch
Abertausende von Varianten an, die gefiltert und eingeordnet werden müssen. Für diese
datentechnische Herausforderung müssen sich Forscher*innen und Kliniker*innen auf
Computerprogramme verlassen.
Diese Arbeit beschreibt MutationDistiller, ein frei verfügbares Web-Programm zur Ana-
lyse von Exomsequenzierungsdaten, das sich an Kliniker*innen und Forscher*innen ohne
bioinformatische Fachkenntnis richtet. Das Programm ermöglicht nutzerorientierte Un-
tersuchungen zur Auffindung der krankheitsverursachenden Mutation(en) aus einer Viel-
zahl von Kandidaten. MutationDistiller kombiniert dabei Genotyp und Phänotyp der
Patient*innen und erlaubt somit einen Fokus auf die Genveränderungen, die im konkret
vorliegenden Fall am wahrscheinlichsten für die weitere Analyse von Interesse sind.
Eine Vielzahl von Phänotypdaten werden akzeptiert, unter anderem HPO, OMIM und
Orphanet-Einträge, Listen von Kandidatengenen, Expressionsdaten, Daten der Gene On-
tology oder auch zu betroffenen Signaltransduktionswegen. Die Ergebnisseite fasst die
Daten in nutzerfreundlichen Tabellen zusammen und zeigt detaillierte Informationen zu
allen Kandidatengenen sowie Hyperlinks zu weiteren Resourcen, um die Einschätzung
der Relevanz der Ergebnisse zu vereinfachen.
Diese Arbeit beschreibt Aufbau, Hintergrund und Nutzung von MutationDistiller sowie
einen Vergleich mit ähnlich gelagerten Programmen. MutationDistiller hat bereits den
Weg in die Klinik gefunden und wurde bisher in über 14.000 Fällen angewendet. Das
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1.1 The human genome
1.1.1 The genetic code
The blueprint for human traits – anything that makes us unique and determines large
parts of how we look, think and behave – is stored in the human genome. Determining
the nature of this information has kept scientists and philosophers busy for centuries.
Ancient thinkers and philosophers such as Hippocrates, Epicurus and Aristotle developed
theories on how traits are determined long before the existence of genes or genomes was
even postulated. In more modern times, breeding experiments conducted by Gregor
Mendel in the 19th century laid the groundwork for what would later be called genetic
research. In the 20th century, molecular approaches slowly led to the realisation that
deoxirobonucleic acid, or DNA, was the carrier of those traits.
After decades of experiments by numerous researchers, each adding to the growing moun-
tain of knowledge, the structure of this large molecule was finally determined by James
Watson and Francis Crick [1] with important contributions by Maurice Wilkins, Ray-
mond Gosling and Rosalind Franklin [2]. Thanks to all these advances and following
research, we now know that DNA consists of repetitions and repetitions of nucleotides.
These nucleotides, or bases, exist in the four varieties Adenine (A), Guanine (G), Thymine
(T) and Cytosine (C) and arrange themselves in base pairs: A pairs with T, and G with
C. Together, they form a double helix which twists and turns around itself, becoming
coiled and tightly packed and organised into 2 sets of 23 chromosomes. These sets of
chromosomes play an important role in inheritance, as each individual receives one set
from their mother and one from their father.
The packing mechanism allows the approximately 2m long helix to be squeezed into the
nucleus of cells which are 1,000,000 times smaller. In addition to this nucleic DNA, a
small portion of the genome is present in mitochondria. In total, all chromosomes and
the mitochondrial genome encode about 23,000 protein-coding genes, the molecular units
of heredity, which are stored in about 6 billion base pairs.
The contents of the human genome – the sequence of the nucleic acid base pairs – can be
read, much like a book. This technique of reading the genome or single genes is referred
to as DNA sequencing and has enabled deep insights into the properties, structure and
organisation of the DNA. The first draft of the human genome – the first complete
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sequence – was achieved in a dramatic head-to-head race in 2001 by the Human Genome
Project and Celera, a private venture established by Craig Venter [3, 4].
This step marked the onset of a new era in genetic research: Knowing the contents of the
human genome sparked a whole new approach to the science of genetics and inheritance,
enabling us to assess the mechanisms behind genetic diseases. As the methodologies
for DNA sequencing improved, the costs dropped dramatically, enabling the inception
of large-scale genomic projects. As a consequence, thousands of full or partial human
genomes have been sequenced to date. Nowadays, even though the details of the genome
are not entirely understood, we have a good insight into the variety and variability of
human genomes and what consequences genetic changes can have for an organism.
1.1.2 From genotype to phenotype
The entirety of an individual’s traits, which are largely determined by the genome as
a blueprint, are often referred to as their phenotype. The genetic blueprint has to be
translated into function: In a multi-step process, genes have to be read, or transcribed,
into ribonucleic acid (RNA) and from there translated into proteins. Those genes that
carry traits are usually termed protein-coding genes (as opposed to other types of genes
which do not encode proteins but take on regulatory functions). Due to their importance
for disease and this thesis, I will focus on protein-coding genes in this thesis and use the
term genes for protein-coding genes unless indicated otherwise.
The processes of transcription – often termed gene expression – and translation are the
basis of molecular functions. They are complex and well-regulated procedures which have
been studied intensively and deserve their own theses. In the following, I will therefore
limit myself to a short, simplified introduction to transcription and translation in humans
with a focus on disease relevance.
Transcription
In the first step of gene expression, a gene has to be transcribed to generate a messenger
RNA (mRNA) molecule. RNA is a molecule quite similar to DNA but comes with three
major differences: First, it is single-stranded (and therefore doesn’t take on the shape of
a double helix). Second, instead of a deoxyribose sugar it contains a ribose sugar; and
third, instead of the base thymine (T) it contains a slightly different base called uracil
(U).
Transcription begins in the promoter region of a gene, more precisely at the transcrip-
tion start site (TSS). There, transcription factors, proteins that regulate the process of
transcription, bind to ensure that gene expression takes place exactly when and where
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it is needed. The DNA splits open to generate a single strand that serves as a template.
From this template DNA, the mRNA can be created by pairing complementary bases to
it – A to T, G to C. The resulting premature mRNA then has to be processed further
to form mature RNA. One main processing step is termed splicing :
The premature mRNA is full of sections which are not present in the mature mRNA,
termed introns. They are removed, or spliced out, leading to an mRNA containing only
exons. Splicing happens at specific sites termed splice sites. For each premature mRNA
molecule, there are several ways for it to be spliced, leading to varying gene products or
transcripts. This means that one single gene can actually generate a number of different
mRNAs (and, in consequence, proteins). These different versions are often referred to as
transcripts.
Non-protein-coding genes are transcribed and undergo maturation steps, but the next
step, translation into protein, does not occur for them. Instead, they take on their
important functions, e.g. for tRNAs the transfer of amino acids.
Translation
In the next step, the remaining protein-coding mRNA has to be translated into a protein
sequence. The mRNA is ‘read’ in 3-letter ‘words’ called codons: Each codon consists of
three mRNA bases and encodes for one specific amino acid. In addition, four codons have
the regulatory function to denote the start and end of the translation process. The start
is determined by the start codon AUG – which plays a double role as it also encodes
for the amino acid methionine – whereas three different codons serve as stop codons:
UAA, UAG, and UGA. The span between start and stop codon is referred to as the
open reading frame, ORF. Regions located within the mRNA but before the start site
and after the stop codon do not become translated and are referred to as untranslated
regions, UTRs. Even though they are not part of the final protein, these regions are still
important because they take on regulatory functions.
Disease relevance
Genetic alterations influencing the processes of transcription and translation can be
the cause of genetic disease. For example, variants in the promoter region or the TSS
can lead to too low or high transcriptional rates, which has been found to influence
susceptibility or survival rates in cancers as well as other diseases [5–7]. Moreover, splice
site aberrations can lead to altered proteins which are not able to fulfil their normal
function. It was recognised some time ago that splice site aberrations are relevant to
cancer [8], and since then further examples have appeared at a steady rate (e.g. [9, 10]).
In addition, faulty splicing has been found to be involved in other genetic disorders such
as the hereditary eye condition retinitis pigmentosa [11, 12]. Thus, a lot of evidence is
accumulating which indicates that alterations affecting the processes of translation and
transcription are relevant to the development of genetic disorders.
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1.2 Studying DNA variation
Human individuality and variability are represented in the genomic sequence: Every
individual carries a multitude of genetic variants – smaller or bigger alterations in the
genetic sequence between individuals – which often have no effect, but are also the
underlying cause for hair colour, height, size, or weight. On average, 1 in every 1000
base pairs is a genetic variant, which across the entire genome amount to millions of
differences between any two individuals on the planet (except for identical twins): The
exact number of variants is hard to gauge and varies widely depending on the study,
methods, reference group, and other factors. However, every single sequencing run of an
entire human genome detects on average 3 to 4 million alterations [13]. These genetic
variants are, in most cases, harmless – like a different spelling of a word. However,
sometimes, differences in the human genome can be harmful and cause disease. Detecting
these harmful alterations and their implications on human health are two major goals in
medicine and research, and they can be addressed by genomic sequencing.
Ever since the basic structure of the genome was determined, and possibly even earlier,
scientists dreamed of reading its content to uncover the secrets hidden in it. The first
method to achieve this at a mid-throughput level was developed in 1977 by Fred Sanger
and colleagues [14] and is based on chain-termination during in vitro DNA replication:
In its early days, Sanger sequencing was conducted using a modified DNA polymerase
called Sequenase. For Sequenase sequencing, the DNA strand to be analysed is combined
with essential components for DNA replication: DNA primer, DNA polymerase and
nucleotides. In addition, chain-terminating dideoxynucleotides (ddNTPs) are added to
the mix. As these ddNTPs lack an OH group required for binding two nucleotides
together, they cause DNA polymerase to terminate elongation. In the classical approach,
this reaction is carried out in four different reaction tubes, each of which only contains
one of the four ddNTPs. The fragments from each of the four reaction tubes are then
denatured and size-separated via gel electrophoresis. By reading the order of the DNA
bands on the gel image, starting at the shortest fragment and ending with the longest,
the sequence of the template DNA can be decoded.
The introduction of polymerase chain reactions, PCR, has since simplified and automated
Sanger sequencing. For instance, the use of dye-labelled ddNTPs, in which each of the
four ddNTPs emits a different colour signal, allows researchers to conduct sequencing in
a single reaction. This method has become the main approach in automated sequencing.
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Modern Sanger sequencing can be used for sequences of up to 900 base pairs and has been
playing a big role in genetic research. It has the advantage of being an accurate method
and was the most frequently used DNA sequencing method for about four decades.
However, in more recent years, the advent of so-called Next Generation Sequencing,
NGS techniques has revolutionised the field of genetics. These techniques allow for the
cheap and fast determination of the entire human exome – the protein-coding part of the
genome – or genome.
1.3 Genetic disease and inheritance
Genetic diseases are disorders which are at least in part caused by disease-causing variants
in the DNA sequence. While the large majority of genetic alterations are completely
harmless, some of them can cause disease or increase the likelihood for the development
of disorders. Frequent harmless alterations are termed polymorphisms and are naturally
occurring variants of which every individual harbours many. If an alteration is known
to cause a disease, it can be described by various terms: Well-accepted descriptions are
harmful variant or disease-causing alteration, as well as mutation, or combinations of
these terms. To distinguish between harmless and harmful alterations, I attempt to
make it clear in the context by adding explanations such as harmless, deleterious, or
disease-causing.
Deleterious genetic alterations can lead to or influence the likelihood of developing a
disease in various ways. In some cases, one single harmful variant can be enough to
cause a disease, in others the disease mechanisms are more complex. In the following
sections I will provide an overview of different genetic disease mechanisms, with a focus
on Mendelian disorders due to their relevance for this thesis.
1.3.1 Complex diseases
In so-called complex diseases, a combination of several DNA variants increases the likeli-
hood of an individual to develop a certain disease. Examples are widespread and include
many civilisation disorders such as cancer, diabetes or cardiovascular problems; diseases
which affect a large number of patients at some point in their lifetime. While complex
disorders are not exclusively genetic – environmental factors such as diet and lifestyle
also play a big role – certain variants are known to increase the likelihood of suffering
from a complex disease. For the development of cancer or other complex diseases, one
deleterious variant is usually not enough to trigger the onset of the disease. Instead, a
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number of variants increase the probability for disease development in an incremental
way, with each variant’s effect contributing with differing effect sizes.
In familial cancers, the effect size of a variant is strongest: an individual is more likely to
suffer from a certain type of cancer at some point in their life if close relatives have been
affected by it and have passed on the alteration. As these variants are rare and have a
clearly deleterious effect by destroying the protein function, they are often referred to as
disease mutations even though they do not directly cause disease. Instead, environmental
factors or additional mutations do still play a role in hereditary cancers.
An example of a familial cancer that made headlines in recent years was the case of
Hollywood actress Angelina Jolie, who decided to undergo double mastectomy in 2013
and removal of her ovaries in 2015 after finding out that she carries a mutation in the
BRCA1 gene. The protein produced by this gene plays a crucial role in DNA repair.
Hence, Jolie’s BRCA1 mutation, combined with a strong family history of breast and
ovarian cancer, was estimated to increase her susceptibility to breast cancer by over
80% and to ovarian cancer by 50%. Angelina Jolie’s example has lead to an increase
in BRCA1 testing [15], which in turn caused debate on the risk of unjustified genetic
testing [16, 17].
However, for many cancer patients neither a familial predisposition nor a lifestyle link
can be established. Frequently in those cases, mutagens or even copying errors during cell
replication lead to somatic mutations. These alterations only occur in a subset of cells
rather than the entire body. Most somatic mutations are harmless, but in some cases
they can lead to the development of certain cancers. In fact, this mechanism, which
can best be summed up as ‘bad luck’, has recently been found to be a leading cause of
non-familial cancers [18].
Complex diseases show great heterogeneity in severity, age of onset, influence of genetic
and environmental factors. Hence, it is a real challenge to establish a link between a
genetic variant and the onset of a complex disease – each factor only contributes with
such a small effect size that it is extremely hard to pinpoint where things went wrong
for the patient.
1.3.2 Mendelian disorders
In contrast to complex diseases with their myriad of contributing factors, in some cases a
single damaging variant in a single gene can be enough to cause a severe genetic disorder.
These disorders are termed monogenic, rare, or Mendelian disorders and affect a large
number of individuals worldwide. Even though each single disease is rare, in 2015 over
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7,000 such disorders were known and approximately 300 new diseases were estimated to
be added each year [19]. Hence, the total number of affected patients lies in the millions.
While dedicated statistics on affected individuals are difficult to come by, 6 to 8%, or
25-36 million patients are estimated to suffer from a rare disease in the European Union
at some point in their lives1. It has to be noted that this number includes non-genetic
rare diseases as well. However, it demonstrates strongly that ’rare’ diseases as a whole
are far from rare.
Many Mendelian disorders manifest in early childhood. They often have severe conse-
quences and pose major burdens on affected families. Examples of early-onset Mendelian
disorders include Cystic Fibrosis, Sickle Cell Anemia, or Phenylketonuria; diseases which
do not only drastically impact life-quality but often lead to premature death. As an ex-
ception to this pattern, a number of rare genetic disorders appear later in life, such as
Huntington’s Disease, which usually manifests between 35 and 44 years of age. Another
prominent example of a Mendelian disorder is Autosomal dominant polycystic kidney
disease, ADPKD, a life-threatening disease in which large kidney cysts eventually lead
to kidney failure. With a frequency of approximately 1 in 1000, it is one of the most
common genetic disorders.
Curing the underlying cause of monogenic diseases requires alteration of the genetic
sequence, a procedure termed gene therapy. This technology does currently not exist for
most disorders. The one example which made headlines recently is the drug Zolgensma,
which received approval of the US Food and Drug Administration (FDA) in May 20192.
This drug addresses the genetic cause of spinal muscular atrophy, mutations in the SMA1
gene. Incidentally, it is also the most expensive drug ever admitted, at USD 2.1 million
per treatment.
In all other cases where gene therapy is not (yet) an option, an early diagnosis can help
doctors to treat symptoms and delay or halt some of the debilitating consequences. Many
countries, including Germany, have introduced newborn screenings to test for a range
of monogenic disorders, enabling diagnosis and potential treatment before the baby’s
first teeth appear. The case of Phenylketonuria (PKU) serves as an example of the
importance of early diagnosis.
PKU is a congenital metabolic disease resulting in a decreased metabolism of the amino
acid phenylalanine. It was first discovered by the Norwegian doctor Asbjørn Følling in
1934 [20]. When untreated, this disorder leads to intellectual disability, seizures, mental





uptake of phenylalanine, and when treated in this way from an early age, babies born
with PKU can grow up healthy and reach a normal life span. Due to the importance
of an early treatment, in many countries newborns are routinely screened for PKU at
a few days’ age. In Germany, a nation-wide test for PKU was introduced in the late
1960s, identifying affected babies at an extremely young age and allowing for optimal
treatment.
However, disease management is not the only argument for early diagnosis: When a
baby with a congenital disease is born, this has a strong impact on the affected families.
The birth – and sometimes early death – of a baby with a congenital disease poses a
strain on the mental health of the parents, who often struggle with feelings of guilt and
responsibility. A molecular diagnosis is of great importance for parents and patients alike
and helps them to better come to terms with the situation [21, 22]. Moreover, it allows
for the assessment of the disease risk for future children by observing the inheritance
pattern of the disease and by offering prenatal tests to affected families.
1.3.3 Inheritance patterns
As genetic diseases, monogenic disorders can be inherited from generation to generation.
In their voyage through the generations, they follow certain patterns which are governed
by Mendel’s laws. By counting traits in pea plants, the Moravian monk Gregor Mendel
(1822-1884) determined the rules underlying inheritance. Mendel observed an organism’s
phenotype – characteristics visible to the outside, such as traits or behaviours – to draw
conclusions on the underlying genotype – the genetic identity that determines a certain,
observable trait. From his experiments, which were largely ignored by scientists for 30
years and rediscovered in the early 20th century, the various modes of inheritance could
be derived. These rules are determined by the organisation of the human genome and
allow for categorisation of the many different Mendelian disorders.
The human genome is arranged in 46 chromosomes: one maternal and one paternal set of
22 autosomes (non-sex-linked chromosomes) and the two allosomes (sex chromosomes,
XX for females and XY for males). Hence, every human carries two copies of each
autosomal gene, one of which is inherited from the mother, and one from the father.
These two versions of a gene are termed alleles.
For sex chromosomes, the matter is slightly different: Males only have one copy of genes
located on the X-chromosome, which they inherit from their mother. Females, on the
other hand, do not carry a Y-chromosome at all. In addition, large parts of one of the X
chromosome are inactivated at random in each cell in females. This mechanism termed
random X inactivation offsets the higher genetic load in females.
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A genetic trait – and hence a Mendelian disorder – can be inherited in different ways:
If a single alteration is enough to cause it, it is inherited in a dominant fashion and the
presence of one disease allele (heterozygous genotype) as well as two disease alleles (ho-
mozygous genotype) will lead to disease. This is often the case for mutations that increase
the function of the protein, so-called gain of function (GOF) mutations. In this case, if
the trait is fully penetrant, every individual who carries the disease allele will develop
the disease. However, GOF variants with a strong effect are subject to a high selective
pressure. Thus, affected individuals born with a GOF mutation often do not survive,
which usually prevents these mutations from manifesting in family pedigrees. Instead,
GOF variants tend to appear newly in an individual as so-called de novo mutations or
in late-onset diseases such as ADPKD.
A special type of dominant inheritance occurs with dominant-negative mutations, which
lead to a gene product with an antagonistic function to the healthy allele. An example
is Marfan syndrome, which is caused by mutations in the FBN1 gene.
In the opposite case, the case of loss-of-function (LOF) alterations, a protein’s function
is reduced or completely abolished. In this case, two defective alleles are required for the
manifestation of a disease as the remaining healthy allele is often still able to maintain
function – therefore, two disease-causing alterations have to be present. Heterozygous
individuals who carry only one copy of the disease allele are usually healthy and termed
carriers. This mode of inheritance is called recessive and the disease allele has to be
present in a homozygous fashion for the disease to manifest. If the second disease mu-
tation necessary for the manifestation of a recessive disorder is not identical to the first
mutation (but, for instance, present at a different location in the same gene), the geno-
type is termed compound heterozygous. Dominant and recessive inheritance patterns
can be linked with autosomes or allosomes, resulting in four main modes of inheritance:
autosomal recessive, autosomal dominant, allosomal recessive, and allosomal dominant.
Figure 1.1 displays a simplified overview of example phenotypes and resulting genotypes.
Figure 1.1: Overview of genotypes and resulting phenotypes. Displays po-
tential genotypes and resulting phenotypes depending on mode of inheritance (MoI).
Harmful alteration indicated in bold and red.
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In autosomal modes of inheritance, both genders have the same probability of suffering
from a genetic disease. For allosomal inheritance, however, some important differences
exist between the genders: As males carry only one copy of each gene located on the X
chromosome, they will be affected by X-linked recessive disorders when they inherit only
one disease allele. Affected males receive their X chromosome carrying a disease mutation
from their mother, who often is unaffected by the disease. Moreover, carrier females can
express an X-linked recessive disorder in varying degrees due to the aforementioned
random X-chromosome inactivation.
Another mode of inheritance plays a role in a subset of genetic disorders: mitochondrial
inheritance. Mitochondria, the powerhouses of a cell, contain a small circular genome
that encodes 13 protein-coding genes. Diseases linked with mitochondria are termed
mitochondriopathies. Although the majority of mitochondriopathies are due to disease
mutations in the nucleic DNA, mutations in genes located in the mitochondria can lead to
disorders such as Leigh syndrome or mitochondrial myopathies. These disorders show a
distinct inheritance pattern: Mitochondria are inherited almost exclusively in a maternal
fashion, leading to a pattern that mimics autosomal inheritance as both genders can be
affected equally. However, this picture can be warped by heteroplasmy, the presence
of several mtDNAs in a single cell [23]: Human cells contain hundreds of mitochondria
in which the individual mtDNA molecules can be slightly different, with only some of
them being affected by a given alteration. Depending on how many of the inherited
mtDNA molecules do not carry the disease allele, the offspring might or might not be
affected by the disease. These processes are determined by chance during cell division
and development [24, 25].
Monogenic disorders can be transmitted following all modes of inheritance introduced
above. However, recessive autosomal inheritance is the most common mode. This is
due to the fact that the selective pressure towards recessive alterations is not as strong
as for dominant ones: Recessive traits can be passed on through healthy carriers for
generations and only manifest in homozygous individuals. In consanguineous families,
where an individual’s ancestors are related, recessive disorders manifest more frequently
as the disease-causing variant has a higher likelihood of being inherited both paternally
and maternally.
1.4 Finding disease causes in Mendelian disorders
The classical approach to detecting the cause of genetic disorders consists of a complex
procedure of various genetic tests: First, candidate regions are determined via linkage
analysis, a method to find genetic markers which are inherited together with the disease
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phenotype (or co-segregate) in an affected family. Genetic markers are genes or genetic
sequences whose chromosomal location is known and which can thus be used to find out
where a disease gene is located.
Second, the physician compiles a list of candidate genes located within those regions
that are most likely to be linked with the disorder based on what is known about their
function. In a third step, the coding sequence of these candidates is then sequenced in
the patients, and, provided the discovery of potential disease mutations, in their relatives
and controls from the same population. Finally, this array is then usually concluded by
functional investigations, or – the gold standard – an animal model to determine the
molecular relevance of a putative pathological alteration.
While this approach has been the standard for decades now, it is both time-consuming
and expensive due to the multi-step set-up. In addition, it is only an option in large fam-
ilies or in cases where many families are aﬄicted as a number of affected and unaffected
members are needed for linkage analysis.
In recent years however, thanks to the advent of so-called Next Generation Sequencing,
NGS techniques, new analysis methods have taken over. While the availability of affected
or unaffected relatives helps in elucidating disease causes, it is not a prerequisite for NGS.
Falling sequencing costs and recent advances in NGS methods not only sparked large-
scale research projects such as GenomicsEngland’s 100,000 Genomes project [26], but
also the identification of connections between genes or mutations and disease. This has
led to a wealth of knowledge – but also to a large amount of data which has to be sifted
and analysed; a task in which we depend largely on computers.
1.4.1 Next Generation Sequencing and bioinformatics
1.4.1.1 Sequencing
DNA sequencing allows us to read the contents of the genome in order to find ’spelling
errors’, i.e. mutations relevant to genetic diseases. Depending on the disease in question,
the availability of candidate genes, and healthy or affected relatives to be sequenced in
parallel, several NGS sequencing strategies are possible:
Panel Sequencing refers to the assessment of a number of candidate genes known to be
involved in certain diseases. These target genes are enriched in the sequencing process by
capturing and isolating them, a step which requires heavy optimisation. Panel sequencing
is used if a patient’s symptoms point towards a specific disease or a group of diseases,
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and it has been widely used in the past (also in combination with Sanger sequencing).
While well-established panels are still widely used, due to dropping sequencing costs,
improvements in data analyses and the complicated optimisation of the enrichment step,
more comprehensive sequencing methods are now taking over [27, 28].
Target-enriched sequencing allows the sequencing of large genomic target areas. Thus,
researchers can decide to target a subsection of the genome or a subset of genes. Selected
regions are hybridised to target-specific probes, which can then be isolated, amplified and
sequenced. One form of target-enriched sequencing is Whole Exome Sequencing, WES, in
which the entire exome, the protein-coding part of the human genome, is analysed. The
exome consists of only a small percentage of the genome – roughly 1% – but is considered
to contain most of the known disease mutations [29]. In exome sequencing, the target
regions have to be captured and enriched. Because it is currently not possible to evenly
capture all target regions, WES has an inherent level of uncertainty. Depending on
which exome version is used – for each reference genome as described in section 1.4.1.2,
various exome versions exist – sequencing results may differ. Nevertheless, its advantages
outweigh the costs. The first diagnosis of a Mendelian disorder using WES was achieved
in 2010 [30] (also see section 1.2) and nowadays, WES is frequently used and currently
considered the most cost-effective method of genetic analysis in clinical and research
settings [27].
However,Whole Genome Sequencing (WGS), the analysis of the entire genome, is steadily
gaining ground as it is the most comprehensive sequencing approach, does not require
any enrichment step and is hence considered to be more powerful than WES in variant
detection [28, 31]. While WGS costs have been prohibitive in the past, falling costs and
technological advances have led to an increased usage of WGS [32]. The first human
genome ever sequenced – the Human Genome Project – was billed at USD 500 million
to USD 1 billion. Nowadays, in a range of recent studies, WGS costs were found to lie
between USD 1,906 and USD 24,810 per test, in comparison to USD 555 and USD 5,169
for WES studies [33] in different countries. As data analysis methods improve, increased
demand is expected to drop the costs even further, leading to the growing importance of
WGS.
Nowadays, most large-scale projects are conducted using NGS methods. Despite these
advances and changes, the ’old-school-method’, Sanger sequencing, still remains used for
smaller projects and the validation of NGS results.
In NGS, it is no longer the sequencing step that is the main limiting factor, but the data
processing: As each sequencing run generates millions of reads and tens of thousands
(WES) or millions (WGS) of variants, it is a major struggle to make sense of this moun-
tain of data. Determining the disease-causing variant in rare diseases is often described
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with the metaphor of finding a needle in a haystack. Bioinformatic methods are indis-
pensable in this task. In the following sections, I will give an insight into the various




For Mendelian disorders, the goal of sequencing is to find the causal mutation(s). In order
to achieve this, the raw fragment reads determined by NGS have to be aligned to a human
reference genome. These reference genomes are compiled from the sequences of different
humans and maintained by the Genome Reference Consortium (GRC). Until genome
version GRCh37, the version before the latest, there has been an attempt to list the more
common variant as the reference allele in cases of polymorphism. The current version,
GRCh38, was published in 2013 and offers alternate sequences for genomic regions known
to be highly variable.
Many secondary sources and applications still use the GRCh37. The human reference
genome can be accessed at different sites, such as Ensembl [34] or the UCSC Genome
Browser [35].
Various algorithms exist for alignment of NGS fragments to a reference genome, with
new alternatives being developed constantly. The choice of algorithm depends on factors
such as run-time, accuracy, and – last but not least – the researchers’ familiarity with a
certain tool. Frequently used algorithms in clinical research settings are BWA [36], one
of the oldest – but still most common – options, and Bowtie [37].
Variant Calling
After mapping, the resulting data has to be scanned for variations, i.e. deviations from
the reference sequence. This step allows researchers to identify various types of genetic
alterations: Single Nucleotide Variants, SNVs, are changes of a single base pair – at
a certain position in the reference genome, the base A might be present, whereas the
patient’s sequenced genome shows a G. They are also the most common type of genetic
variation. Other, more complex types, are insertions or deletions, InDels, where one or
more bases are inserted additionally to or deleted from the genomic sequence. Structural
variants are larger alterations which span 1000 bases or more and can hardly be detected
using WES. They include inversions, the flipping of a genomic sequence, translocations,
its shifting to a different location, and copy number variants, CNVs, which are defined as
DNA segments of one kilobase or larger that are present at a variable copy number when
compared against a reference genome [38]. Technically, CNVs are large InDels, but due
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to their size are treated separately from those smaller scale alterations. The detection of
large structural alterations is where WGS excels, as it is capable of detecting even large
structural aberrations spanning many genes, independent of whether the break point is
located in an exon or not.
Various algorithms tailored to the analysis of different variant types exist. As SNVs and
small InDels are the most common variants and the easiest to detect, these are usually
the first ones to be investigated and thus the most relevant for my thesis; I will hence
examine and elucidate them in more detail in the following sections.
During the variant calling step, it can also be determined whether an individual’s geno-
type is homo- or heterozygous at a given location, a process termed genotyping. When
attempting to determine the disease-causing mutation(s), the genotype provides valuable
information that helps to reduce the number of candidates.
Short variants (single nucleotide variants, insertions and deletions) are usually exchanged
in variant call format (VCF) files. A VCF file lists the genomic location – the chromosome
and base position – for each variant found in an individual, combined with additional
information3 such as allele counts, reading depths, quality scores or, if available, the
genotype. Subsequent analyses – the search for the disease causing mutation – are then
carried out on the VCF files.
1.4.1.3 Variant annotation
Variability leads to a large number of variants detected in a patient: WES analyses
usually yield tens of thousands of variants, whereas for WGS, this number lies in the
millions – on average 3 to 4 million variants are found in a single WGS run [13]. Most of
these variants are completely harmless, and to distinguish the harmful from the harmless
is not a trivial task. Therefore, in a first step, these variants have to be annotated with
information on their disease potential. As manual curation of these vast amounts of data
is not an option, computer tools have to be employed for this task. These programs assess
the disease-causing potential of a candidate variant by linking it with known biological
data: Depending on where exactly an alteration is located and how it might alter the
gene product, its effect can vary widely from being completely harmless to having a
devastating impact on a patient’s life.
The protein-coding part of the genome has been studied quite extensively in the last
decades, so the scientific community has a lot of information about the potential impact
of a genetic alteration within a coding sequence. For instance, it is easily conceivable
3https://samtools.github.io/hts-specs/vcfv4.2.pdf, accessed 28.12.2018
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that mutations leading to a premature stop codon (see section 1.1.2), thus truncating the
protein, are extremely harmful. Other variants can lead to the exchange of an amino acid,
which can be harmful or harmless, depending on what this change means for the function
of the protein. In other cases, even though there is an alteration in the genetic code,
there is no amino acid exchange. These synonymous alterations are mostly considered
harmless.
Even variants located outside of the coding sequence can have a severe impact on gene
function: alterations near splice sites, for example, can lead to heavily altered proteins
which might not be functional. Moreover, alterations in untranslated regions can be of
disease relevance by having a regulatory impact. Thus, the exact location, and the effect
of a mutation on the protein, serve as indicators for the likelihood of a variant in question
to cause disease.
A wide range of information on proteins, their function and structure can be found in
databases such as Swiss-Prot [39], a manually annotated and reviewed knowledge base
of curated protein information, such as protein function and classification.
Other important databases store information on known variants: For example, a large
number of variants are already known to be harmless or, in the opposite case, have been
found previously to be involved in genetic disease. dbSNP [40] is the most comprehensive
example of a repository of known SNVs and InDels in humans which contains harmless
alterations as well as known disease-causing mutations. The 1000 Genomes (1000G)
project [41] and ExAC [42] collect data from healthy individuals. ExAC, for instance,
contains data from over 60,000 individuals who do not suffer from a rare early-onset
disorder but who might be carriers of disease alleles.
In general, variants found in ExAC or 1000G are not likely to be involved in the de-
velopment of severe, early-onset genetic diseases and can be excluded in many cases.
For instance, a variant with a frequency of 1% in ExAC can usually be excluded when
assessing a disease which appears in 1 in every 3 million cases. In addition, a genome-
wide version of ExAC, gnomAD [43], is now available. In contrast to variant databases
with a focus on harmless variants, disease mutation sources such as ClinVar [44] or the
commercial platform HGMD [45] store data on known disease-causing variants.
However, all variant databases have to be treated with care as they might not be suitable
to answer every specific question. For instance, while frequent polymorphisms found in
ExAC can be excluded from further analysis, the data also includes not-so-rare recessive
disease-implicated alterations (e.g. cystic fibrosis mutations): As healthy individuals
might be heterozygous carriers of a recessive disease mutation, one would expect to
find these variants in the database, even though they are of clear disease relevance in
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homozygous patients. In addition, a patient’s ’private’ variants – alterations which are
harmless but not (yet) listed in any of the databases – cause problems. This is especially
problematic for populations that are not covered in the databases (until recently most
non-caucasian populations). Thus, it is necessary to not only rely on variant databases
but to take additional information into account. For example, the location of a variant
within the gene and its effect on the protein product play a role, together with information
on evolutionary conservation. More insight into the data sources described above can be
found in chapter 2.2.
Sophisticated computer programs are able to pull the information provided in a range of
databases together and deliver an estimate for each variant in a VCF file. One of these
programs, MutationTaster4, was developed in our research group [46, 47] and will be
explained in further detail below (see section 2.2).
Some examples of other tools capable of annotating candidate variants or of predicting
their disease-causing potential are Poly-Phen2 [48] and SIFT (Sorting Intolerant from
Tolerant, [49]), which analyse variants based on sequence homology and the physical
properties of amino acids, and can both only annotate coding non-synonymous SNVs.
VAAST2 [50], on the other hand, combines the predictions of a number of programs.
It offers a greater range of capabilities and can score coding and non-coding variants.
Another combination tool is CADD, which integrates a range of annotations into one
metric by contrasting variants that survived natural selection with simulated mutations
[51].
Different tools draw their conclusions by different means and hence may come to contra-
dicting results. It is known that the capabilities of various tools and their concordance
vary widely [52, 53]. To account for this and to allow users to compare results between
different software, in recent years a number of tools combining the output of several tools
have been developed such as CADD [54], the Variant Effect Predictor (VEP, [55]), and
the aforementioned VAAST2 [50].
1.4.1.4 Variant prioritisation: patient information
As NGS projects deliver large numbers of variants, even a list of previously filtered
potentially harmful annotated variants is daunting and has to be committed to further
scrutiny. In order to find the causal mutation, the variants have to be prioritised based
on additional information: A clinician can determine variants located in disease-relevant
genes for a specific case by including patient- or case-specific data such as symptoms,
the expected gene function, or candidate genes from gene panels. In combination with
4http://www.mutationtaster.org
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a variant’s effect on the gene product, this information enables powerful filtering or
prioritisation of candidate alterations. The more accurate – hence the more personalised
– the descriptions are, the more likely it is to detect the real culprit.
This combination of genotype and phenotype allows alterations labelled as ‘harmful’
that do not fit with the disease in question to be excluded. At the same time, alterations
considered less severe by the computer program but which perfectly match the patient’s
phenotype could become more relevant. In this way, the rather broad categorisations
into ‘harmful’ and ‘harmless’ become more tailored, allowing a step towards personalised
medicine.
Phenotype
A patient suffering from a genetic disease exhibits specific symptoms, which can be
identified and classified by their clinician. In the clinic, the entirety of all symptoms
observed in a patient is often referred to as their phenotype. Taking the phenotype into
account can greatly facilitate diagnosis by establishing a link to known disorders, similar
diseases, and by suggesting candidate genes.
Phenotyping – the identification of a patient’s symptoms and their systematic and thor-
ough documentation and communication – is not a trivial process, especially in diseases
or syndromes which can show a high degree of heterogeneity [56, 57] and exhibit multiple
symptoms resulting from just one mutation. Therefore, correct phenotyping is crucial for
successful diagnostics. Major efforts have been made to categorise symptoms by using
controlled vocabulary, ensuring that every expert uses the same terms to describe a given
symptom. In a second step, these descriptions have been put into context by organising
them in systematic collections, so-called ontologies (see section 1.4.1.5 for details).
The Human Phenotype Ontology (HPO) [58], for example, is a systematic collection
of disease symptoms observed in patients suffering from (mostly monogenic) genetic
diseases, and their connections. The information stored in ontologies such as the HPO not
only helps to streamline the complex process of determining the patient’s phenotype but
also enables computational applications: HPO data can be used by computer programs
to calculate and quantify the relationship between symptoms and their relevance.
The phenotypes organised in the HPO have been connected to OMIM (Online Mendelian
Inheritance in Man, [59]) and Orphanet [60], large-scale collections of known genetic dis-
orders, their symptoms, known disease genes, and related research. This allows for a
systematic, computational assessment of genetic variants, symptoms and their pheno-
typic relevance.
Gene panels
In many cases, lists of candidate genes, so-called gene panels, are already known for
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a certain group of disorders. One well-studied example is the Kingsmore panel [61],
a collection of genes known to be involved in rare recessive genetic disorders which
manifest in early childhood. It has been revised and curated many times and is used
for routine diagnostics worldwide. This is a major aid when assessing the relevance
of candidate variants for a particular case. These panels can either be used for for
enrichment in targeted sequencing (see section 1.2) or as virtual panels to reduce the
number of candidates in WES or WGS sequencing projects. Many clinics use in-house
panels for various diseases and disease groups. In an attempt to generate a reliable
knowledge-base from this wild growth of gene panels, Genomics England’s PanelApp5 is
an initiative to generate expert curated gene panels for the scientific community. It stores
expert reviewed virtual gene panels for over 200 human disease groups. Fore example,
the PanelApp Familial dysautonomia panel currently contains 22 expert-reviewed genes
of relevance for the disease, 14 of which are quoted with a high confidence (’green’ genes).
Virtual panels such as the ones provided by PanelApp connect the benefits of panel
sequencing – lower number of candidates, easier analyses – with the advantages of exome
sequencing. Therefore, the restriction to virtual panels in cases with a clear phenotype
is a convenient way of improving data analysis. However, this approach cannot detect
new disease genes as it only works for genes that are already known to be involved in a
certain disease or set of symptoms.
Gene function
In cases where no mutation in any known disease gene can be found, clinicians have to
take other traits into account: Knowledge about function, expression and interactions of
a gene or gene product can help to close in on the disease cause. In contrast to relying
on known disease-gene links, this approach has the advantage of opening the door to
discovering hitherto unknown disease genes. There are a number of data sources that offer
varied insights into the functions of and connections between genes and gene products.
The Gene Ontology (GO) [62] stores machine readable knowledge on the function of genes
and gene products in an ontology. GO data is often compiled from many organisms such
as mice or zebra fish and humans. The GO addresses the functionality of genes and
their products in a computer readable manner and stores the relations between them.
By including this knowledge into the investigation of the disease gene, the search can be
restricted to relevant genes, such as the relevant protein class (e.g. ion channel) for a
given case.
Another approach is to look at the involvement of genes in molecular or signalling path-
ways: Resources such as Kyoto Encyclopedia of Genes and Genomes (KEGG [63]),
Reactome [64] and WikiPathways [65] store this information. Particularly in cases where
5https://panelapp.genomicsengland.co.uk/
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laboratory data indicate a defect in a metabolic pathway, incorporating this information
into the search for the disease cause can help to identify candidate genes and variants.
A similar approach is feasible in patients who are suffering from a disease limited to
certain organs or organ groups. For instance, if a patient is plagued by a genetic disease
which manifests itself in the skin, the disease gene might be expected to be expressed in
the skin. To collect a list of candidate genes, the inclusion of gene expression data might
be a valid option in this case. A large number of experiments determining the expression
patterns of genes are conducted in laboratories around the world. Findings from various
groups or projects are stored in ExpressionAtlas [66], a manually curated open science
resource offering access to data on gene and protein expression.
1.4.1.5 Ontologies
Ontologies are a powerful way of defining the basic concepts of a research domain, as
well as the relationships between those concepts [67]. They serve as a valuable reference
for researchers and clinicians to search and exchange (biological) data, and they allow
information from heterogeneous methods and sources to be merged. In the case of rare
diseases and human genetics, two major ontologies shed light on genes and their functions:
The aforementioned Gene Ontology (GO) and the Human Phenotype Ontology (HPO)
are valuable resources for variant prioritisation as they allow the evaluation of a candidate
gene’s relevance for a given disease or group of symptoms.
Originally, the term ontology was (and is still being) used in the field of philosophy. It
comes from ancient Greek and describes the study of existence and being. In information
technology, it has been given a slightly different meaning:
Probably the best known definition of modern-day ontologies was coined in 1995 by
Thomas Gruber [68], who identifies an ontology as an explicit, formal specification of
a shared conceptualisation. This short phrase sums up the core concepts of ontologies:
First, the descriptions have to be precise and clear (explicit). Second, they store specifi-
cations in a machine-readable way (formal), and third, there is a shared understanding
of an abstract concept which is represented by the ontology’s conceptualisation. This
conceptualisation is described in classes, attributes and relationships capturing the rel-
evant distinctions in an abstract way while still being as clear as possible about the
meaning of the terms. Together, they form a level of data model abstraction and dis-
play knowledge about individual terms, their properties, and their relationships between
each other. To allow for computational usage, ontologies are specified in standardised
languages enabling abstraction from the structures.
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Ontologies can be depicted as a graph: Each term (or class) is a node and the relationships
between them are edges of the graph. There is usually a loose hierarchy with descendant
terms being a more specialised description of their ancestors. However, a term can
have more than one ancestor, organising the ontology in a structure termed directed
acyclic graph (DAG). Most frequently, terms are equipped with a unique identifier which
allows them to be stored and managed independently from a lexical, human-readable
description, thus reducing errors. Moreover, this step allows the content stored in a term
to be changed or updated later on without altering the ID.
As an example for a DAG, figure 1.2 shows the HPO term Aplasia/Hypoplasia of the
brainstem (HP:0007362) and its first ancestors and descendants.
The relationships between the terms can be described in different ways, such as is_a,
part_of, or is_opposite_of. In biological ontologies, they are often reduced to is_a, sim-
ple class-subclass or ancestor-descendant relationships: In figure 1.2, Hypoplasia is_a
subclass of Aplasia/Hypoplasia of the brainstem, which in turn is_a subclass of Ab-
normality of brainstem morphology. The further we traverse down the graph, the more
specific a description becomes. As more and more types of relationships are being added,
for instance in the GO (e.g. negatively_regulates) and the HPO (e.g. is_opposite_of ),
the graph may contain circles and is hence not a clear DAG anymore. However, for com-
putational methods, is_a and part_of are still the most commonly used relationships.
The structure of ontologies is particularly useful for determining the importance or speci-
ficity of a given term:
Based on information theory, Philip Resnik introduced an information-based measure
for semantic similarity in the 1990s [69], which is nowadays an accepted method to
compare semantic similarities in ontologies and taxonomies. In information theory, the
information content of a concept is higher the less abstract it is. This can be expressed
mathematically. The information content IC of a concept c (e.g. a node in the ontology)
is measured as:
IC(c) = −logp(c)
where p(c) is the probability of finding c in a given domain. In an ontology, this prob-
ability is usually expressed by the fraction of annotated terms for a concept – which in
turn can be expressed as a term’s specificity.
The graph structure of an ontology allows us to determine the descendants and ancestors
that are directly connected to a term. These appear below or above the term in the graph,
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Figure 1.2: Excerpt of the graphical representation of the HPO. This figure
shows the HPO term Aplasia/Hypoplasia of the brainstem (HP:0007362) and its rela-
tionships to its first ancestors and descendants. HP:0007362 has two different direct
ancestors, HP:0002363 and HP:0002977, which it is connected to via an is_a relation-
ship.
and indicate a higher or lower degree of specificity. This concept will be elaborated further
in section 4.1.2.1.
1.4.2 Current variant prioritisation tools
As computational data analysis is absolutely indispensable to make sense of the masses
of results obtained by NGS methods, it comes as no surprise that a large number of
computer tools aimed at different user groups have been developed over the last years. I
will limit myself to phenotype-driven software for variant prioritisation in WES projects,
as these are the most relevant for this work. In this section, I will give an overview of
recent programs, compare their capabilities and describe advantages and shortcomings
of the various approaches.
As described above (see sections 1.4.1.3 and 1.4.1.4), variant prioritisation generally con-
sists of two steps: The candidate variants are annotated and filtered by severity, and
the list of remaining candidates has to be prioritised based on additional information
such as the patient’s phenotype. Current tools usually combine these steps and offer a
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comprehensive analysis of WES data. However, the various software options differ in
many ways and cater to different needs. A lot of early solutions were aimed at bioin-
formaticians and provided their output in scores without any interpretation. Nowadays,
however, more and more clinicians prefer to analyse their own data [70], for which they
are the main experts, and this calls for software that they can use easily and readily. As
extensive computational training is not compatible with a busy working life in the clinic,
these users require different software: Their focus is on easy and intuitive tools which
allow them to work with their patient’s data in a convenient way.
Another distinction between the available tools is the types of data they accept. Earlier
tools such as eXtasy [71], Phen-Gen [72], or the Exomiser [73] are largely based on
the HPO to characterise the patient’s phenotype. In a range of other recent computer
programs, there are often more data entry options. Phevor [74] and PhenIX [75] for
instance, allow multiple ontologies, whereas ANNOVAR [76] can take various disease-
related terms as input. Other software, such as OVA [77], BiERapp [78] or QueryOR [79]
are web-based frameworks which allow retroactively refined analyses but are not available
without registration (QueryOR, BiERapp). Figure 1.3 displays an overview of recent and
widely used web-based tools for the phenotype-based prioritisation of candidate variants.
State-of-the-art variant prioritisation tools are capable of analysing a wide range of data
and cover many different cases. However, many of them have still not found their way
into routine clinical applications as they are often too complex for clinical use or do
not provide enough information for users to draw meaningful conclusions from their
predictions. In addition, most of them can only accept non-synonymous SNVs and are
limited to nuclear DNA. Another major hurdle for clinical use is file size restrictions, as
many tools cannot handle complete VCF files.
A recent paper by Shyr et al. [70] stated the importance of usability and easy access
for the success of sequencing projects. However, NGS analysis software is still often
developed by bioinformaticians without taking clinicians and geneticists on board. Thus,
a number of tools are only available as command-line scripts or source code which has
to be compiled and installed locally, which is of little use for many clinical applications.
A recent example is TAPER [80], a variant prioritisation tool which was published as
source code in 2016. Even the installation of software itself can cause an obstacle for
clinicians who work on different computers and usually do not have the administrative
rights to install software.
The output of many tools can pose another difficulty for daily clinical use: In order to
make sense of the results and to be able to draw further conclusions – which might have
implications on the treatment of the patient – clinicians and geneticists need compre-
hensive information. However, most tools – even recent ones – deliver their results in
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Figure 1.3: Current variant prioritisation tools. Depicted is an overview of the
features of current web-based variant prioritisation tools. Published in Hombach D et
al. MutationDistiller – user-driven identification of pathogenic DNA variants. NAR
Web Server Issue. 2019. doi:10.1093/nar/gkz330
flat tables or files containing a number of scores rather than offering further data on the
biological context and the disease relevance of a specific data point, thus limiting their
use for clinical applications [70].
Moreover, many tools do not provide hyperlinks to external resources, thus forcing the
user to manually search the Internet for further information on their data. While this




To close the gap between the clinic and bioinformatics, and to provide the means for
personalised NGS analysis, in the course of my PhD project, my colleagues and I have
developed MutationDistiller (https://www.mutationdistiller.org), a variant prioriti-
sation tool for use in clinical cases. It was developed in close collaboration with clinicians
and human geneticists, taking their needs and requirements on board. As a consequence,
the program is freely usable online and does not require any software installation. We
aim to make usage as convenient as possible by offering a set of default user modes aimed
to fulfil the needs of different user groups. Thus, we aim to provide software which can
be used by clinicians, researchers and geneticists without extensive knowledge of bioin-
formatics. MutationDistiller has already found its way into the clinic and has seen over
14,000 analyses to date.
1.5.1 Technical information
MutationDistiller’s programmatic structure follows the classical three-tier-structure6 where
the different functions fulfilled by a software – presentation, application processing, and
data management – are separated in three layers:
Presentation tier or User Interface (UI): This Front End is the interface the user
sees. Access is often provided via a web browser.
Logic tier: This layer is also termed application server tier ormiddle tier. It coordinates
the application and contains mechanisms to run the user commands and to return results,
thus connecting the other two layers.
Data tier: This Back End is where data are stored and retrieved; thus it usually contains
a database. It passes the information to the logic tier, from where it will be returned to
the user.
The advantage of the three-tier architecture is that the user only needs to have a web
browser installed, without the need for additional software on their computer. In addi-
tion, for the developers, the three-tier architecture usually has advantages as it is less
labour-intensive than distributed software: The entire control over software and data
stays with the developers – in case of updates, developers can push these changes to the
web-version in one step, without having to worry about distributed versions. This is one
of the main reasons why MutationDistiller is available as a web-version only.
6https://en.wikipedia.org/wiki/Multitier_architecture, accessed 28.12.2018
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MutationDistiller was written in the programming language Perl 57. Dedicated Perl
modules, which are discrete software components, contain all the functions necessary to
fulfil MutationDistiller’s function. In these modules, functions are sorted and grouped ac-
cording to their purpose. The modules reference and call each other, access the database
and connect with the Front End.
MutationDistiller combines the powers of two tools previously generated in our research
group: MutationTaster (http://www.mutationtaster.org, [46]), a variant effect pre-
dictor, and GeneDistiller (http://www.genedistiller.org, [81]), a gene ranking tool –
hence the name MutationDistiller. In the next two sections, I will briefly introduce those
tools and their capabilities.
1.5.2 MutationTaster
The variant effect predictor MutationTaster started in 2008 [47] and is now freely avail-
able online in its second version [46] at http://www.mutationtaster.org. It is able to
predict whether a variant is most likely harmful or harmless. While users can also man-
ually enter individual alterations, in the NGS age the tool is mainly working on entire
VCF files. MutationTaster conducts in silico tests and employs a Naïve Bayes classifier
to distinguish deleterious mutations from harmless variants: Each variant is sorted into
either ‘harmless’ or ‘harmful’. The tool can handle coding and non-coding alterations,
SNVs as well as short InDels. Moreover, it is not limited to protein-coding regions but
can also annotate alterations located in introns and the untranslated regions.
For each variant, MutationTaster has four different prediction options: Disease causing
indicates that the tool’s Naïve Bayes classifier found enough evidence to consider a given
variant to be harmful. Variants causing frame-shifts and leading to nonsense-mediated
decay, or that are listed as ’pathogenic’ in ClinVar, are labelled disease causing automatic
whereas variants known to be harmless from databases such as 1000G or ExAC are
labelled polymorphism automatic. Finally, the polymorphism label denotes variants that
the classifiers considers harmless.
When users upload their data to MutationDistiller, the program sends the information
to MutationTaster to determine the pathogenicity of the submitted variants. In a second
step, the variants (or the genes those variants are located in) are then ranked and excluded




The gene-ranking part of MutationDistiller is based on GeneDistiller (http://www.
genedistiller.org) which was published by our research group in 2008 [81]. GeneDis-
tiller allows lists of candidate genes to be ranked according to how well they match a
myriad of user-definde criteria. GeneDistiller takes regions from linkage intervals or sim-
ple gene lists as input and is also able to conduct whole genome or mitochondrial genome
analyses. Users can filter for and highlight genes fulfilling a number of criteria such as
cellular localisation, expression levels or phenotypes. Moreover, the tool prioritises the
gene lists according to user-defined criteria and weights. Users can also compare their
target genes to genes that show similar expression patterns or interactions. However, we
found that the multitude of options together with a crowded user interface can overwhelm
users and make analyses with GeneDistiller cumbersome. Hence, in MutationDistiller,
we have not only added new resources but also adapted the tool to the requirements
of NGS projects, and trimmed the user interface as well as the underlying algorithm to
provide a user-friendly tool.
1.5.4 Combining genotype and phenotype
By connecting the powers of MutationTaster and GeneDistiller, MutationDistiller com-
bines a patient’s genotype with their phenotype. For the genotype, variants from panel
sequencing, WES, or even WGS studies can be uploaded in VCF format. The pheno-
type can be entered in a multitude of ways: MutationDistiller accepts common ontology
terms such as HPO symptoms or GO terms, diagnoses as OMIM and Orphanet entries,
identifiers for molecular pathways (WikiPathways, Reactome), and expression data (Ex-
pressionAtlas). Candidate genes can be entered manually or as panels via Genomic
England’s PanelApp.
In the output, MutationDistiller displays information about a variant and the gene it is
located in on one page: In a summary table, the top variants are listed together with
crucial information such as gene symbols, known diseases caused by mutations in this
gene, and genotype occurrences in 1000G and ExAC, as well as coverage and compound
heterozygosity. Further data on each gene is listed below, offering a comprehensive
overview of each candidate gene and variant and their relevance for the specific case.
If the causative variant cannot be determined by an initial search, MutationDistiller
offers the option to refine the query by adding or removing terms which have come up
in the meantime. Thus, the program allows users to customise the hunt for the culprit
in an iterative way.
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In the following chapters, I provide an overview of the integrated data sources and
structure of the database. Moreover, further information on the program is given, such
as technical data, the scoring mechanism and a comprehensive description of the input
and output options. I will explain the development and validation steps and describe
use cases for MutationDistiller. Finally, I will give an outlook of future developments.
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2 MutationDistiller: Data integration
In order to accomplish large data-driven projects, such as the prioritisation of the myriad
of candidate variants generated in WES or WGS projects, huge amounts of data from
various sources have to be brought into context. This process of assembling data from
heterogeneous backgrounds and sources in one framework is termed data integration.
Two main ways of integrating data exist:
Uniform Data Access or Virtual Integration keeps the data in their various source
systems and provides access to them directly during the data query process (usually via
the Internet). As such, in each query, the data are gathered together and the output
is only saved for a short amount of time. A main advantage of this approach is that
no additional hardware needs to be provided for storage of the information. Moreover,
there is no delay in the uptake of data updates from the source system. However, this
comes with a loss of control: No version management is feasible and no control over the
data structure is given. In addition, updates can cause severe problems, especially if
the database structure becomes altered. Bandwidth limitations can also cause issues, in
particular with large data sets. Server failures or, even worse, the potential abandonment
of servers may let data queries run dry.
Physical Integration or Common Data Integration on the other hand refers to the
creation of a new system which stores a copy of the data from the source systems. The
data can be stored and managed independently in a Data Warehouse. One example of
this approach is the Ensembl Genome Browser [34] (see section 2.2). A disadvantage of
this solution is that a system to store and handle the source data has to be provided.
Moreover, updates to the source data will have to be manually kept up with.
However, physical integration comes with a number of advantages: First, it allows for
flexible data management and the combination of data from heterogeneous sources and
in different formats. In addition, the function of the data system is independent from the
source system, generating better stability. Data updates can be planned and organised
while the data can be checked for validity more easily than is the case for externally stored
data. Finally, for the usage of the software, physical integration offers a major advantage
as well: The run-time of the program will be reduced in comparison to virtual integration
as locally stored data can be queried much more quickly. Due to these advantages,
we decided to physically integrate the data sources used by MutationDistiller. In the
following sections, I will give an overview of databases in general, as well as the sources
used by MutationDistiller and their integration into the tool.
MutationDistiller: Data integration 29
2.1 Databases
In this data-driven day and age, databases are a popular way of storing and managing
data. Databases are persistent repositories stored in a computer system; meaning that
the data is supposed to be available even after the software application using or creating
it is closed. A single database table can be compared to a simple spreadsheet table. The
real strength of modern data repositories is provided by relational database management
systems, RDBMSs. These are software programs specifically designed to hold the data
of related repositories. RDBMSs store relational databases, which contain their data
in collections of relations, or database tables. A relation is defined as set of tuples – or
database entries – belonging to a given data domain. A database’s tables can therefore
be seen as permanently stored relations. In these tables, columns represent properties
(or attributes) while rows hold the values for these properties.
All related tables are held together in one or several database schemas, which contain
not only the tables but also the connections between them.
RDBMSs offer a number of advantages: First of all, they are optimised for large amounts
of data, and therefore handle them with great speed (scalability). Moreover, several users
can access the database simultaneously through standardised interfaces, making queries
secure and convenient. Finally, the information stored in different tables is usually re-
lated, making it quick and easy to cross-reference data. Transaction control ensures that
a database query that accesses different tables but belongs to one logical task will either
be concluded in its entirety or not at all, without allowing simultaneous write-access.
An example of transaction control is the transfer of money from one account to another:
Taking money out from one account without putting it safely into the destination ac-
count would not make sense (and probably have the bank lose their customers within
no time). Thus, the transaction will only be concluded all-together – or not at all. In
addition, transaction control is pivotal for multi-user tables by ensuring that only one
user can modify the same data at a given time.
To facilitate one of the main advantages of databases, fast and convenient access to the
data, database indices exist. An index, like the index of this thesis, is an ordered list
of the values of one or more attributes stored in a relation, and allows each entry to be
found faster without having to search the entire relation. This is particularly important
for large tables as it can speed up the search process considerably. Indices can combine
multiple different attributes and each table can hold many different indices.
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2.2 Data sources
2.2.1 MutationTaster predictions
To assess the pathogenicity of a variant, MutationDistiller relies on the predictions gener-
ated by a functional prediction tool developed in our group, MutationTaster [46, 47] (see
1.5.2 for more information). MutationTaster employs a Naïve Bayes classifier to predict
a variant’s likelihood to be harmful. To do this, it relies on a number of data sources
itself. A list of MutationTaster’s data sources can be found in table 2.1. Some of the
data integrated into MutationTaster are also available from MutationDistiller directly
and will be described in further detail below.
Data source/tool Description
ENCODE project [82] Encyclopedia of DNA Elements; repository
of functional elements of the human genome
(https://www.encodeproject.org/)
Ensembl [34] Central, freely available data warehouse of genome
data for various species, including human and mice
(https://www.ensembl.org/index.html)
1000G [41] 1000 Genomes Project; public catalogue
of human variation and genotype data
(http://www.internationalgenome.org/)
dbSNP [40] Collection of simple genetic polymorphisms
(https://www.ncbi.nlm.nih.gov/projects/SNP/)
ClinVar [44] Aggregated information on human vari-
ation and its connection to disease
(https://www.ncbi.nlm.nih.gov/clinvar/)
Entrez Gene [83] Integrated gene information on a wide range of species
(https://www.ncbi.nlm.nih.gov/gene)
ExAC [42] Exome Aggregation Consortium. We include
ExAC genotype counts and loss-of-function scores
(http://exac.broadinstitute.org/)
Grantham Matrix [84] Formula for differences between amino acids
PhyloP [85], PhastCons [86] Computer programs to predict the evolutionary conser-
vation of a given nucleotide
UniProtKB [39] Database of protein sequences with annotations
(www.uniprot.org/)
HGMD public [45] Human Gene Mutation Database; non-redundant
collection of disease-relevant DNA alterations
(http://www.hgmd.cf.ac.uk/ac/index.php)
* bl2seq [87] Tool for the alignment of DNA sequences
* MaxEntScan [88] Human splice site prediction tool
* Polyadq [89] Tool for the detection of human polyadenylation sites
Table 2.1: MutationTaster data and tools integrated into MutationDistiller.
This table lists the various data sources and tools that are used by both MutationTaster
and MutationDistiller. Tools are marked with an asterisk. Please note that in the origi-
nal MutationTaster version, the splice site tool was nnsplice [90], which was replaced by
MaxEntScan in later versions. Details on MutationTaster data sources and integrated
tools can be found in [46, 47].
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2.2.2 Genetic data
MutationDistiller, similar to its inspiration GeneDistiller, uses a gene-centric approach
to integrate the many different data sources that come together within the software. In
order to combine and connect these sources, we use the gene level as a mediating point
and map or link all information to Entrez gene IDs provided by the US National Center
for Biotechnology Information (NCBI) [83] and/or gene identifiers from Ensembl (ENSG)
[34]. These identifiers define each protein-coding gene individually and hence enable us
to cross-reference data. In MutationDistiller, this allows us to provide prioritised lists of
variants and their connected genes based on a myriad of options.
2.2.2.1 Ensembl
Ensembl [34] is a joint project between the European Bioinformatics Institute (EMBL-
EBI) and the Wellcome Trust Sanger Institute which begun in 1999 to automatically
annotate genome data. In its Genome Browser1, it provides access to genome annota-
tions for multiple vertebrate species. Since its online launch in 2000, it has grown into a
central, open resource for genome information which is used by many researchers from
various fields. Its core component is the Ensembl Genes database which currently pro-
vides genome data and annotations for 135 mainly vertebrate species. The information
content varies between species, with data for humans and model organisms such as mice
and zebrafish being the most extensive. The Genome Browser provides convenient access
to the data and visualises gene information, genetic sequences and annotations on the
web. For data annotation, Ensembl relies on an automated process in which annotations
of transcripts are based on experimental evidence: The automated pipeline uses mRNAs
and protein sequences from public databases such as the European Nucleotide Archive
ENA at EMBL-EBI, UniProtKB, or NCBI RefSeq. Moreover, transcript annotation data
may be derived from other sources such as the Havana/Vega set [91] and the Consensus
Coding Sequence (CCDS project, [92]), a collaborative project providing an overview of
protein-coding regions with identical annotations for humans and mice. The Genome
Browser is particularly suited for single search requests. For large-scale queries, Ensembl
data is available in various ways. Data from the database can be downloaded or queried
dynamically for virtual data integration. In addition, BioMart [93] offers access to En-
sembl data sets. Expression and protein data obtained from Ensembl are described in
sections 2.2.5.2 and 2.2.6, respectively.
Ensembl data used in MutationDistiller is mainly accessed through MutationTaster’s
prediction results. In addition, MutationTaster and MutationDistiller use the protein
1https://www.ensembl.org/index.html
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repository UniProt/Swiss-Prot hosted by Ensembl. Currently, MutationTaster is based
on Ensembl build 37.
2.2.2.2 Entrez Gene
Entrez Gene is a genome database hosted and run by the NCBI. It offers a web interface
and download providing easy access to gene-specific information. Entrez Gene stores a
large array of data and provides information for specific transcripts. For many tran-
scripts, a direct mapping to Ensembl Transcripts is available. Wherever possible, this is
used by both MutationTaster and MutationDistiller. MutationDistiller also uses addi-
tional data available from Entrez to provide further information on a gene, such as Entrez
Synonyms, which accounts for the fact that a number of genes are known under different
names or abbreviations, or Gene Positions, which determines the genomic locations of
a gene. Moreover, Entrez genes are linked to NCBI GeneRIFs, myriads of tweet-like
explanations on the function of a particular gene (max. 255 characters). They are as-
sociated with a specific Entrez Gene database entry and link to a scientific publication
supporting GeneRIFs. We downloaded GeneRIFs and display them in MutationDistiller
to allow users to get a quick insight into a gene’s function and relevance. Moreover, we
use the Entrez gene identifier to link between Ensembl and NCBI data for each gene.
2.2.3 Variant databases
Variant databases allow to assess the relevance of a candidate variant and to put it
into context. Thanks to previous research and their occurrence in healthy individuals,
many variants are already known to be harmless, whereas others have been found to be
involved in genetic disease. Thus, by using the information stored in those databases,
a large number of known harmless variants in a WES project can be excluded from the
candidate list, while known disease alterations will have to be considered with greater
care.
2.2.3.1 1000 Genomes Project
The 1000 Genomes Project (1000G, [41]) ran between 2008 and 2015 with the goal to
find the majority of genetic variants with a frequency of at least 1% in the populations
studied. Data generated by the 1000G project has been made available to research
communities and is now coordinated by the Data Coordination Centre at EMBL-EBI.
Each sample was planned to be sequenced to 4X genome coverage. While sequencing
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at this depth cannot detect every single variant in each sample and is not sufficient
to determine the exact genotype at each location, it can still discover most alterations
even with low frequencies. In the project’s last stage, data from numerous samples was
combined to enable accurate assignment of the genotypes in each sample at all the variant
sites detected in the project. 1000G samples were obtained from healthy individuals with
no known congenital disorder. Thus, variants found in the 1000G database are expected
to be harmless and to not be involved in the development of rare, Mendelian diseases.
However, as described in the introduction, this has to be taken with care as carriers
might have been included in the data collection. Therefore, it has to be noted that
the database might still contain harmful alterations (e.g. ones involved in complex or
late-onset diseases or heterozygous alterations for recessive disorders).
2.2.3.2 Exome Aggregation Consortium Browser (ExAC)
The Exome Aggregation Consortium (ExAC) Browser [42] is a curated repository of
exome sequencing data from various NGS projects worldwide. It provides data from
over 60,000 unrelated individuals who were sequenced as part of population genetic
as well as disease-specific studies. However, data from individuals affected by severe
paediatric disease have been removed. Thus, for rare early-onset Mendelian disorders,
variants found in a homozygous state in the ExAC database can usually be excluded
from further analysis. As with 1000G data, however, individuals included in the samples
might have been heterozygous carriers of disease mutations. A genome-wide version of
ExAC, gnomAD [43] exists, which is currently being integrated into MutationDistiller.
2.2.3.3 dbSNP and ClinVar
dbSNP [40] and ClinVar [44] are public repositories of genetic variation run by the NCBI.
dbSNP, or the NCBI Short Genetic Variations (SNV) database, is a collection of known
short genetic variants in various species. Despite its name, it is not restricted to single
nucleotide variants but also includes other types of variation, such as short insertions
and deletions, short tandem repeats (microsatellites) and polymorphisms consisting of
multiple nucleotides (multinucleotide polymorphisms). It contains harmless polymor-
phisms as well as alterations corresponding to known phenotypes. As such, it provides
an archive of genetic variation across and within a number of species and allows for
comparisons. To distinguish between harmful and harmless alterations, dbSNP variants
are assigned to levels of severity such as pathogenic, probable-pathogenic, probable-non-
pathogenic and non-pathogenic. Variants with clinical information are compiled in the
clinical database ClinVar and can be accessed and downloaded separately. For a subset
MutationDistiller: Data integration 34
of ClinVar cases, phenotype information is provided as well, which we used for the de-
velopment of our program. MutationDistiller displays and treats data from dbSNP and
ClinVar independently.
2.2.4 Phenotype repositories
MutationDistiller aims at illuminating the molecular cause of Mendelian disorders by
connecting the patient’s genotype with their phenotype. This allows the user to filter
out variants which do not fit the phenotype while having a closer look at alterations in
genes which have previously been found to be linked with a matching phenotype. To
enable this, MutationDistiller includes phenotype data from a range of different sources.
2.2.4.1 Online Mendelian Inheritance in Man
Online Mendelian Inheritance in Man (OMIM, [59]) is a comprehensive collection of hu-
man genes and diseases focusing on the relationship between genotype and phenotype.
It contains data on over 15,000 genes and all known Mendelian disorders. Long before
the online age, it started as Mendelian Inheritance in Man (MIM) in the early 1960s,
generating a manual list of Mendelian phenotypes and disorders. The online version
began in 1985 and was uploaded to the Internet to become freely available to the public
in 1987. Today, it is hosted and authored at the McKusick-Nathans Institute of Genetic
Medicine at the Johns Hopkins University School of Medicine and builds the basis for
many downstream applications on the connections between genetics and human symp-
toms (see section 1.4.1.5). However, the full OMIM data is currently not freely available
anymore.
2.2.4.2 Orphanet
Orphanet [60] is a repository of rare diseases founded in France by the INSERM (French
National Institute for Health and Medical Research) in 1997. Since 2000, it has become
a European undertaking and is now hosted by a Consortium of 40 countries worldwide.
Amongst other services and tools, it provides an inventory of rare diseases2, connected
with various resources such as OMIM to enable the systematic storage and assessment
of known rare disorders in humans. Moreover, with Orphanet Rare Disease Ontology
(ORDO)3, a structured vocabulary for rare disease linking relationships between genes
and disorders is currently being developed to support computational analyses.
2https://www.orpha.net/consor/cgi-bin/Disease_Genes.php?lng=EN, accessed 11.06.2019
3http://www.orphadata.org/cgi-bin/inc/ordo_Orphanet.inc.php/, accessed 11.06.2019
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2.2.4.3 Mouse Genome Database
The Mouse Genome Database (MGD, [94]) is a community data resource providing a
comprehensive knowledgebase on mouse genes, genetic markers and genomic features. In
addition, their associations to phenotypes and other properties are given as well. Muta-
tionDistiller displays MGD phenotype data to allow users to find genes which are known
to cause a particular phenotype in mice. Adding mouse phenotypes as an additional
layer of information can be particularly useful for genes which have not yet or cannot be
studied extensively in humans. We are using the link between MGD entries and human
diseases4 to provide users an opportunity to search for genes causing a certain mouse
phenotype.
2.2.4.4 Human Phenotype Ontology
The main goal of the Human Phenotype Ontology (HPO, [58]) was to create a standard-
ised, computer-legible vocabulary of human phenotypic abnormalities in order to allow
large-scale computational assessment of human phenotypes. By giving an identifier to
each term and denoting their relationship to other terms, it allows phenotype data to be
structured and helps to describe a patient’s symptoms as accurately as possible. Cur-
rently, the HPO contains over 11,000 terms. It is organised in five subontologies The main
subontology is phenotypic abnormality with its description of disease phenotypes. Addi-
tional subontologies describe different aspects of the phenotypic abnormalities: mode of
inheritance, mortality/aging, frequency and clinical modifier.
To organise the phenotypes and connect them with known disease genes, the HPO draws
on data from OMIM and other sources. Nearly all clinical OMIM descriptions have been
mapped to HPO terms. In addition, all Orphanet entries have been annotated, together
with over 60 recurrent syndromes from DECIPHER [95], a web-based source of plausibly
pathogenic genomic variants from well-phenotyped rare genetic disorder patients. By
organising the data in an ontological structure, the HPO enables computational usage of
the vast knowledge stored in these heterogeneous data sets. Moreover, regularly updated
phenotype to gene mappings are provided. Phenotype-gene annotations are conducted
using OMIM as a mediator platform. As OMIM compiles all symptoms for a given
disease – irrespective of whether this disease can have multiple genetic causes or display
multiple subsets of symptoms – this leads to a degree of uncertainty as not necessarily
all symptoms of a disease are connected with every gene in the OMIM list. In addition,
a layer of insecurity is added as neither there is no distinction between symptoms that
are mandatory and others that might possibly or even only rarely occur in a given
4http://www.informatics.jax.org/diseasePortal, accessed 11.06.2019
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disorder. Nevertheless, the HPO and its gene-phenotype annotations are a valuable and
widely used resource in human genetics. We obtained the OMIM-to-gene annotations
via Medgen, the human medical genetics interface from the NCBI5 and incorporated
them into MutationDistiller to allow users to find genes linked with a specific phenotype.
Thus, by describing the patient as accurately as possible, clinicians are able to reduce
the relevant data to the most fitting genes.
2.2.5 Gene and protein function
The function of genes can be described in a number of different ways, such as a gene’s
role within molecular pathways, its disease relevance or its expression patterns. Muta-
tionDistiller combines a range of data sources linked with the various dimensions of gene
functions:
2.2.5.1 Gene Ontology
The Gene Ontology (GO, [62]) is an ontological representation of genes and their func-
tions at the molecular, cellular and tissue system level. It has grown to contain over
40,000 concepts annotating gene functions based on over 100,000 scientific publications.
The GO is organised in three sub-ontologies storing molecular function, cellular compo-
nent, and biological process of genes and gene products. Depending on the main point
of interest taken, genes or gene products can be described via one or more of the sub-
ontologies. For example, the gene product cytochrome c can be seen as part of all three of
the sub-ontologies: Oxidoreductase activity focuses on the molecular function, whereas
oxidative phosphorylation refers to the biological process and mitochondrial matrix to
the cellular component6. Using GO terms and their relationships in MutationDistiller
allows us to find genes fitting a patient’s phenotype via their function without being
restricted to what is known about human genes. For example, for a patient suffering
from an enlarged kidney, their clinician might be able to find candidate genes by filtering
the WES data via GO term GO:35564: regulation of kidney size.
2.2.5.2 Expression data
Expression data can be helpful especially in cases where the disease is limited to certain
tissues or organs. Limiting the search to genes known to be expressed in the tissues of
interest might help to reduce the list of candidate variants, in particular if no disease is
5ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/mim2gene_medgen, accessed 11.06.2019
6http://www.geneontology.org/page/ontology-documentation, accessed 11.06.2019
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already known for the patient’s symptoms. ExpressionAtlas [66], hosted by EMBL-EBI,
is an open repository giving access to results from gene expression studies worldwide.
It provides expression data from various species and under varying biological conditions
(e.g. different tissues, cell types, and diseases). Different experimental methods are
included, such as RNAseq or microarray data. All experiments can be accessed and
visualised online as well as downloaded. Currently, data from over 3,000 experiments
are available, which have been curated and re-analysed with standardised methods to
enable continuity. For MutationDistiller, we have downloaded the Tab Separated Values
(TSV) files for a number of data sets that we consider to be interesting for clinicians
and human geneticists: These are baseline experiments, i.e. samples that had not been
submitted to any experimental treatment, came from healthy tissues and organs, and
were obtained by different experimental means and at various developmental stages. A
list of the experiments included in MutationDistiller can be found in table 2.2.
data source experiment development accession number
ENCODE [82] RNAseq adult E-MTAB-4344
FANTOM5 [96] RNA-CAGE adult, fetal E-MTAB-3358
GTEX [97] RNAseq adult E-MTAB-5214
HPA [98] Protein Expression adult E-PROT-3
HPA [98] RNAseq adult E-MTAB-2836
PRIDE [99] Protein Expression adult, fetal E-PROT-1
Table 2.2: MutationDistiller expression data sources. Overview of expression
data included into MutationDistiller. Expression data was obtained from Expression-
Atlas [66]. Accession number: ExpressionAtlas identifier.
Saving and displaying gene expression data is a complex task: Different data sources
cannot be combined or compared directly as expression levels are highly specific from
experiment to experiment and from tissue to tissue. Moreover, there is a big difference
between a gene not being expressed in a given tissue and a lack of expression data (zero
value vs. NA).
We thus had to design ways to store a wide range of individual expression data sources
while enabling users to easily access them. To achieve this, we decided to regard expres-
sion levels relative to median gene expression: For each tissue, we calculated its median
gene expression across all genes and for a given data source, denoting all genes expressed
below this median as not-expressed in the tissue. In addition, we calculated whether a
gene’s expression in a given tissue is high (i.e. lies within the 75th percentile) or very
high (i.e. within the 90th percentile). We saved this information in our database for each
gene and experiment separately. We define genes as not expressed in a certain tissue if
their expression levels lie below the median for all genes across this tissue – if a user
selects to display only expressed genes, any genes expressed below the tissue median are
removed from the results list.
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In addition, we decided to collect tissues together in biological groups as each of the
various data sources offers a wide range of different tissue types. The ENCODE data
(E-MTAB-4344), for instance, has relatively broad tissue categories (brain, liver, heart,
etc.), whereas the FANTOM5 data (E-MTAB-3358) contains sub-tissues (e.g. brain:
amygdala, brain meninx, occipital lobe, etc.). In order to make search and selection more
user friendly, we gathered each data source’s sub-tissues together to generate groups,
which can then be selected in the MutationDistiller interface. All the FANTOM5 brain
sub-tissues, for example, are now collected within the category ’brain’. We stored these
groups and sub-groups in our database, separately for each data source.
In the user interface, we grouped these categories again into organs (brain, heart, liver,
etc.), tissues (muscle, placenta, throat, etc.) and systems (reproductive, nervous, im-
mune, etc.). In addition, we identify the different data sources by the experimental
means with which they were generated (RNA-CAGE, RNA-Seq and protein expression)
as well as the developmental stage of the tissue (adult or fetal). As mentioned above,
MutationDistiller considers a gene to be not expressed in a certain tissue group (e.g.
brain) if its expression is lower than the median of all sub-groups (e.g. amygdala, brain
stem, medulla...) that contain data for that particular gene. For all groups that a gene
is expressed in, the sub-groups are listed in the results as well. A compilation of the
expression groups can be found in table B.1 in the appendix.
2.2.5.3 Metabolic and signalling pathways
In cases where a phenotypic characterisation of the patient does not lead to success, i.e.
for hitherto unknown disease genes, the inclusion of information on gene function can
be helpful. One intuitive way of describing the function of a gene is to refer to their
role in molecular pathways: Within a single pathway, numerous events (such as DNA-
binding), protein complexes, reactions (e.g. adenylation), translocations and regulatory
events can be represented in a simplified graphical view, enabling enhanced understand-
ing of complex concepts and networks. We have included molecular pathway data into
MutationDistiller to allow users to tackle rare, unknown cases not obviously linked with
known disease genes.
The Kyoto Encyclopedia of Genes and Genomes (KEGG) [63]) is a database platform
covering various aspects of biological and cellular functions linked with genes and gene
products. In its KEGG Pathway collection, manually drawn pathway maps are provided.
An identifier is allocated to each map, denoting meta-information about the pathway.
While the web-services are accessible freely to the public at http://www.kegg.jp/kegg/
pathway.html, data download is only available with a paid academic subscription. As
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MutationDistiller can only include open data, we have incorporated the last free data
download of the KEGG Pathway collection. This data is from 2011 and does hence not
entail up-to-date information. We thus decided to display the data but to not provide
KEGG as a searchable resource or include it into the score.
Reactome [64] is an open access, open source database of molecular pathways providing
access to curated and peer-reviewed date. It provides visualisation of pathways and
tools for their analysis, enabling, amongst others, research and genome analyses. In its
database, it combines molecules and nucleic acids interacting in reactions into biological
pathways. Reactome was founded in 2001 and is now headed by a group of researchers
from institutes around the globe.
WikiPathways [65] is a similar, open and collaborative project providing access to curated
biological pathways. It is based on the MediaWiki software7 employed by Wikipedia com-
bined with a graphical pathway editing tool. For each pathway, a wiki page displays the
current diagram and offers references, descriptions, download options, and supporting
information. Pathways can be edited and updated by the community and changes be
monitored to ensure quality of the entries. We have downloaded the Gene Matrix Trans-
posed (GMT) files available for download on WikiPathways. These are lists of gene sets
containing the pathways and the genes within these pathways.
As an example of the visual representation of pathways, figure 2.1 shows the Bone Mor-
phogenic Protein (BMP) Signalling and Regulation pathway, a pathway of importance
in embryogenesis and development.
2.2.5.4 Gene panels
Especially for patients with well-characterised diseases or symptoms, gene panels are
known to be a great tool in the hunt for disease alterations [100, 101]. Targeted gene
panels contain lists of genes known to be linked with a certain disease or group of diseases.
They can either be used to sequence the panel genes only or as virtual gene panels to filter
the results of a WES or WGS for panel genes, bringing down the number of remaining
candidates substantially to variants located in genes matching the case. MutationDistiller
incorporates virtual gene panels from various sources:
The Kingsmore panel [61] is a collection of genes which have been found to be involved
in rare recessive genetic disorders manifesting in early childhood. After having been
reviewed and assessed in multiple ways, various versions of the panel exist which differ
in small aspects. We have decided to include the Kingsmore panel version included
7https://www.mediawiki.org/wiki/MediaWiki, accessed 11.06.2019
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Figure 2.1: WikiPathways Bone Morphogenic Protein (BMP) Signalling
and Regulation pathway (WP1425). Displays the graphical representation of the
BP pathway stored in WikiPathways. Provided by Waagmeester A, Pico A, Hanspers
K, Osman BM et al. Accessed 17.09.2018.
in the heterozygote screening conducted by Pränatal-Medizin München as provided by
Orphanet8. This version of the panel contains 550 genes for 258 different diseases.
Another prominent virtual gene panel which we integrated into MutationDistiller is the
HPO panel. This panel contains all the genes which have been connected with any HPO
term, thus any gene which has ever been found to be linked with a disease symptom. We
obtained version 2 of this panel with 3061 genes from the Institute of Medical Genetics,
Charité Berlin.
MutationDistiller also contains the ACMG actionable genes panel, which is a list of genes
published by the American College of Medical Genetics and Genomics (ACMG). It com-
piles genes of medical interest: These are genes for which the knowledge of a mutation
within it might be beneficial to the patient as action (prevention) can be taken. An ex-
ample is the APOB gene, which is known to be involved in familial hypercholesterolemia.
Knowledge of a mutation in this gene allows medical action to be taken, which could be
8https://www.orpha.net/data/dgs/DE/DgsID109383.pdf, accessed 23.12.2018
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life-saving. The most recent version of the ACMG actionable genes panel, ACMG SF
v2.0 [102], is incorporated into MutationDistiller.
In addition to published panels, many clinics or sequencing services have generated their
own gene panels from scientific literature. These can simply be used in MutationDistiller
by copying a gene list into the respective entry field. To generate a reliable knowledge
base for virtual gene panels commonly used in human genetics, Genomics England’s
PanelApp9 offers expert curated gene panels from and for the scientific community. Cur-
rently, gene panels of varying size for over 2000 human conditions are available from
their services, which we have downloaded and integrated into MutationDistiller. Pan-
elApp is a community-driven approach that calls experts into action: Each virtual panel
is reviewed and curated by clinicians or geneticists who are experts for a certain disease,
gene or disease group. The panel genes are sorted into three categories depending on the
confidence with which they have been added to the list. ’Green’ genes are intended to
be diagnostic-grade and according to their criteria require evidence from three or more
unrelated families or from 2-3 unrelated families where there is strong additional func-
tional data. All other genes which do not match these guidelines are rated as ’amber’ or
’red’ and should not be used in diagnostic settings, according to PanelApp’s creators.
2.2.6 Protein families
To provide a user-friendly interface allowing clinicians and human geneticists to draw
their own conclusions about a variant’s relevance, MutationDistiller provides as much
information as necessary and possible in one place. The inclusion of protein information
might help users decide for themselves which variants to assess with further scrutiny and
which ones to dismiss. MutationDistiller hence displays protein-related data from three
major resources to assist users.
PFAM [103, 104], hosted by EMBL-EBI, is a database collecting protein families. It
represents them by multiple sequence alignments and hidden Markov models (HMMs) to
display similarities between proteins and to allow insights into protein functions. PFAM
draws on data from the UniProt Reference Proteomes10. The information stored in
PFAM is accessible online and can be downloaded as well.
InterPro [105] is another protein platform providing functional analyses of protein se-
quences. It offers an insight into the functions of a protein by storing predicted protein
domains. Predictive models (signatures) provided by various member databases such as
9https://panelapp.genomicsengland.co.uk/, accessed 11.06.2019
10https://www.uniprot.org/help/reference_proteome, accessed 11.06.2019
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PFAM, PANTHER [106] or SMART [107] are used to classify proteins. It is run by a
consortium of protein databases from around the globe and hosted at EMBL-EBI.
2.2.7 Protein-protein interactions
2.2.7.1 STRING
STRING [108] is a database of protein-protein interactions developed by a consortium
of European institutions. It contains experimental data as well as computational pre-
dictions. Currently, data on almost 10 million proteins from over 2000 organisms is
included, which is available both online and can be downloaded. We have integrated
human STRING data into MutationDistiller to display STRING interactions and to
provide hyperlinks to relevant entries.
2.2.8 Mitochondrial data
While the mitochondrial genome with its 37 genes (including 13 protein-coding genes)
only makes up a tiny fraction of the human genome, mitochondriopathies place a burden
on a large number of patients [109]. Mitochondriopathies include diseases linked with
proteins generated in the mitochondria directly and those that are shuttled into the
organelle - the latter being the vast majority: Most of the more than 1,000 different
mitochondrial proteins are encoded by nuclear DNA and have to be shuttled into the
mitochondria to fulfil their function. MutationDistiller provides access to three different
resources on mitochondrial data.
The Maestro score [110] is a broadly used scoring system to predict mitochondrial pro-
teins encoded by nuclear DNA. It uses eight genomic data sets on targeting sequence
prediction, protein domain enrichment, presence of cis-regulatory motifs, yeast homol-
ogy, ancestry, tandem-mass spectrometry, co-expression, and transcriptional induction
during mitochondrial biogenesis to determine the likelihood for a protein to be functional
in mitochondria.
MitoCarta [111] is an inventory of mitochondrial proteins hosted by the Broad Institute11.
It was generated by experimental means using mass spectrometry of mitochondria from
fourteen different tissues. In addition, protein localization was assessed in large-scale
GFP tagging/microscopy. The results were then integrated with other data sets, gener-
ating an inventory of 1158 human and mouse genes. Data are available online and can
11https://www.broadinstitute.org/scientific-community/science/programs/
metabolic-disease-program/publications/mitocarta/mitocarta-in-0, accessed 11.06.2018
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be downloaded. We have incorporated MitoCarta data into MutationDistiller to allow
users working in the field of mitochondriopathies to assess at a glance whether a certain
gene is relevant in their case.
Mitopred [112] was a web server for the prediction of mitochondrial proteins encoded
by nuclear DNA in eukaryotes. It based its predictions mainly on Pfam domain data
comparing mitochondrial and non-mitochondrial locations. Data was available online
and downloadable. While the service has since been discontinued, MutationDistiller still
displays Mitopred data from the latest update (08/2016).
2.3 MutationDistiller’s database
2.3.1 Database structure
All of MutationDistiller’s data are stored in one database but organised in different
schemas of related tables. These schemas – which are often distinct data entities but
reference each other – mirror logical categories that the data can be sorted into. The
data used by MutationDistiller can be divided into two main categories: Project-related
data and general data, with general data falling into five schemas. In the following, I
will describe the database structure and relationships between the different tables.
2.3.1.1 Query Engine schema
The Query Engine (QE) was first developed for MutationTaster and has since been
adapted for MutationDistiller. It reads the submitted VCF file line by line and saves
the information in our database. During this process, it generates a number of project-
specific tables and adds information to our variant tables. The QE database schema is
visualised in figure 2.2 and the QE potocol is described in 3.
The submitted variants are saved in our variants table (all_vars), which compiles all
variants that have ever been uploaded to MutationDistiller and information related to
them. Double entries, variants in the wrong format or with a coverage below a user-
defined minimum threshold are discarded. Upon upload, the variants are checked for the
correct version of the reference genome (currently GRCh37). In a next step, variants
that are found in the variant databases 1000G or ExAC with a genotype count exceeding
custom-set thresholds are filtered out as well. By default, variants that appear at least 10
times in a homozygous state in ExAC and 4 times in 1000G are discarded; however these
settings can be changed by the user. In addition, the Query Engine upload page allows
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users to restrict analysis to certain genomic regions and to only analyse homozygous
alterations – if this is the case, all variants not matching these criteria will be filtered
out. Only the variant itself is committed to the all_vars table. There, it is assigned
a variant number (var_number), which serves as a primary key and at the same time
allows other QE schema tables to access the information.
Some of the QE tables store and summarise data for all projects that have been up-
loaded to MutationDistiller thus far: all_projects provides meta-data on all MutationDis-
tiller projects such as email address (if provided), project name, or number of variants.
all_results, on the other hand, contains all MutationTaster results and background in-
formation (such as the results of the underlying tests conducted by MutationTaster) for
all variants in the database. This helps to speed up run times and saves database re-
sources as each variant has to be saved to the database and analysed only once – after
committing it to the database it can be easily accessed later on.
In addition to the variant-related tables, separate tables are generated for each new
project, allowing MutationDistiller to quickly and simply access the projects if a user
enters the relevant ID: Input information, i.e. a project’s variants, their coverage, and
homozygosity state are saved in an input_ProjectID table. In addition, the QE schema
contains tables for each project that identifies areas that could be present in a compound
heterozygous state. These compound heterozygosity tables (comphet_ID_VARSEL) are
generated depending on the selected MutationTaster variant severity predictions: Each
variant combination that a user analyses (e.g. severe variant settings for both variants
versus severe first variant and benign second variant settings) generates a new compound
heterozygosity table during the prioritisation (see sections 4.1.1 and 5.1.4 for details).
Therefore, this table is technically also part of the prioritisation protocol. Nevertheless,
in our database set up we decided to include it in the QE schema because - as a project-
specific table with long-term storage - it belongs to the QE logically.
For further information on the QE, its processes and features, please refer to chapter 3,
for the QE’s user interface to 5.
2.3.1.2 MutationDistiller database schemas
Public
Some of the data are accessed by several of our applications and are stored in the schema
type public. This schema was first established for the gene-ranking tool GeneDistiller
[81] and has since grown to accommodate a range of tools developed in our research
group. This schema contains all gene-related data, such as gene names and numbers and
their position. In addition, external data sources referring to those genes are stored in
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Figure 2.2: Overview of MutationDistiller’s Query Engine Schema. Displays
the database tables stored in the QE schema and their references, important attributes
and primary keys (PK). Please note that for reasons of legibility, some attributes have
been omitted in this depiction.
this schema as well, including OMIM and OrphaNet data, GO and MGD entries and
pathway data.
Ensembl
The Ensembl data used by MutationDistiller is stored in the schema type ensembl37_85.
This schema includes gene and transcript tables obtained from Ensembl, exon and tran-
script data, and links to Entrez gene ids, which enables us to connect Ensembl data to a
multitude of other resources stored in the public schema. In addition, the expression-gene
links are stored in this schema as well. It currently contains version 85 of GRCh 37 data
stored in Ensembl, but other versions can be added and run in parallel.
HPO
HPO data is stored in a separate schema, hpo. It contains HPO terms, their ancestors
and descendants together with synonym and opposite terms. In addition, the relevant
genes linked to each HPO entry are stored in this schema.
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Expression
The expression schema contains expression data obtained from ExpressionAtlas and con-
nects to the ensembl37_85 schema.
Build37
The build37 schema of our database stores all genome version-specific data, such as
the variant databases as well as the genotype counts for the Query Engine and user
interface. This schema is therefore crucial for the variant effect predictions conducted
by MutationTaster, which form the basis of MutationDistiller’s sorting and filtering
mechanism.
2.3.1.3 MutationDistiller entity-relationship diagram
The tables, schemas and relations of a database can be represented in an entity-relationship
diagram (ERD), which allows the database’s structure to be visualised. Figure 2.3 dis-
plays such an ERD in a simplified version for the tables and schemas used by Muta-
tionDistiller. In this depiction, I have decided to omit a number of tables for reasons
of legibility. A comprehensive ERD displaying all the tables and schemas employed by
MutationDistiller can be found in the Appendix.
Figure 2.3: MutationDistiller database ERD. A simplified view of the database
tables used by MutationDistiller and their connections, references and keys. The colours
indicate different database schemas. Specific sub-schemas (HPO, GO, expression and
protein/gene tables) were removed from this ERD to provide a legible diagram. Symbols
denote data types: 123 - numeric; ABC - text. Please note that only selected columns
are shown, as a comprehensive ERD is located in the Appendix.
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3 MutationDistiller: Query Engine
When a user submits variants stored in a VCF file to MutationDistiller, the tool com-
mits the data to its database, sends the variants to MutationTaster for pathogenicity
predictions, and records the received predictions in the database. All these steps are
conducted by MutationDistiller’s Query Engine (QE) and take place independently from
the prioritisation process. In this chapter, I will explain the various steps undertaken by
the QE. In the following chapter 4, I will then describe the prioritisation process which
gets started when a user calls a project from the database, and in chapter 5 the interface
of QE and main program.
3.1 File upload
When starting a new MutationDistiller project, the user submits their VCF file to our
QE system. The QE was first developed for MutationTaster and has since been adapted
for MutationDistiller. It consists of a number of Perl scripts, which are called via shell
scripts to manage all projects. The submitted projects are scheduled using the freely
available resource manager TORQUE1. The Perl scripts that make up the QE send jobs
to TORQUE, which organises them according to file size: Smaller projects get processed
faster than larger ones, and large projects may be split up and worked on in paral-
lel. In addition, two customised Perl modules contain query-engine related functions:
QueryEngine.pm governs general query engine tasks, and SendMail.pm sends notifica-
tion emails from the query engine. These Perl modules are collections of Perl functions
that were not written especially for MutationDistiller but are shared by all our programs.
From MutationDistiller’s start page2, the QE can be accessed via a hyperlink which
leads to a HTML page for file upload3. The QE interface is described in further detail
in section 5.1.2.
3.2 Query Engine workflow
In order to store all the relevant data in MutationDistiller’s database, the program goes
through a dedicated routine which I describe in the following and which is depicted in
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As a first step, the MDQE_start script checks all submitted data for coherence and
usability. For example, it ensures that a VCF file has been submitted, that the minimum
coverage was entered as a valid number, or that the given candidate genes exist. If
something is wrong, the program returns an error message, alerting the user to the
problem and pointing them in the right direction. If all the submitted data are correct,
MutationDistiller generates a running project number and a unique, random, six-digit
access code. These two components are combined to form the case ID enabling users
to access their project. The project number allows us to keep track of the cases seen
by MutationDistiller thus far. The case ID ensures that only the user holding the ID
can access the case. In addition, it allows the unique identification of a project: While
several users might give their projects the same title, each ID is only allocated once. A
typical case ID would be 123_456789, where the digits in front of the underscore are the
project number and the six digits after are the access code.
The start script then saves the user settings and proceeds to the next script. This
script, VCF2DB, reads the VCF file line by line and extracts the data for each variant:
chromosomal position, reference and alternative allele, coverage and genotype. It checks
whether the variant’s coverage is greater than the entered minimum coverage and discards
variants that do not fulfil this criteria. In addition, it checks that the same variant is
not yet located in the database (in table all_vars) and only commits new variants to
this table to ensure low run-times and to save data storage space. Furthermore, the
first 40 SNVs are checked for correct annotation (i.e. reference allele matching genome
version 37). If this check fails, the whole process will be aborted and an error message
will be sent to the user via the errors script. Please note that for reasons of clarity, this
step has been omitted in the graphical representation. Finally, all project-related variant
information passing all the filters will be saved to table input_ID.
In the next script, Map2Transcripts, the QE maps the submitted variants to transcripts
to be able to send it to MutationTaster for variant effect predictions. This is achieved for
each variant and for each possible transcript consecutively. To speed up the process and
to decrease the amount of data that are returned from the database, only variants for
which no MutationTaster result is stored in all_results are queried. Variants are mapped
to all protein-coding transcripts with which they overlap (same chromosome and variant
start before/equal to transcript end and variant end after/equal to transcript start).
In the end, a temporary database table transcript_ID containing variant-transcript pairs
is created for the project. This list is then handed over to the CreateTasterPackages
script, which splits it into a number of packages to be run in parallel in the next step –
the MutationTaster analyses. The number and size of the packages depends on the size of
the project: Large project will be sent in a great number of different packages. Splitting
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up large projects in this way allows the upload to be sped up tremendously and ensures
that under normal circumstances, a conventional WES run will be handled within a few
minutes at most, and significantly faster if it contains a large amount of variants that have
already been seen by MutationDistiller. The packages are then sent to MutationTaster
by the Query_MT script, which in turn saves all the results in the all_results table.
This script goes through each entry in transcript_ID, runs the MutationTaster analysis
and saves the results. It then deletes the variant-transcript pair from transcript_ID.
The following script CallMissingTests, ensures that all sets and tests have been completed
and saved by checking whether there are any remaining entries in transcript_ID. If this is
the case, it calls CreateTasterPackages again. Finally, MDQE_finish compiles statistics,
saves the total number of variants included in the project to the database and notifies the
user of the completion of the project. In addition, it calls the script CleanUp to remove
all temporary tables. The errors script mentioned above might be called at any point
where a problem is encountered, such as incorrect variant formats or missing entries.
After the project has been successfully processed by the QE, the user will be redirected
to an overview page with data on the analysed file. From there, they can directly access
MutationDistiller’s main page with the project identification number (ID) pre-filled. In
addition, if an email address was entered, the user will receive one email notifying them
of the submission and one after upload and analysis have been completed, together with
a link to their project and the project ID.
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Figure 3.1: Simplified view of MutationDistiller’s Query Engine workflow,
part 1. chr: chromosome, pos: position, ref/alt: reference/alternative allele, MT:
MutationTaster, DB: database, MDQE: MutationDistiller Query Engine.
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Figure 3.1: Simplified view of MutationDistiller’s Query Engine workflow,
part 2. chr: chromosome, pos: position, ref/alt: reference/alternative allele, MT:
MutationTaster, DB: database, MDQE: MutationDistiller Query Engine.
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Figure 3.1: Simplified view of MutationDistiller’s Query Engine workflow,
part 3. chr: chromosome, pos: position, ref/alt: reference/alternative allele, MT:
MutationTaster, DB: database, MDQE: MutationDistiller Query Engine.
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4 MutationDistiller: Prioritisation
4.1 Filtering, scoring and providing information
Once a user has uploaded a project to our QE and it has been committed to our database,
the data can be accessed via the project’s ID and security code. Users can call their
projects and enter case-specific information, which MutationDistiller will use to deter-
mine the most likely candidates in a given case.
Upon data submission, a Perl CGI script MDresults.cgi is called which governs and runs
the Perl functions necessary for MutationDistiller to run its course. The various functions
called by this script are organised in a number of customised Perl modules: Input reads
the input and passes it on to subsequent functionalities. DBqueries contains functions
that retrieve data from the database, Scoring governs the scoring and weighting process,
and Output.pm generates the output page. In addition, Errors generates error messages,
Settings.pm governs MutationDistiller’s settings, and Debugging.pm holds functions for
internal debugging.
Other customised Perl modules are used by all of our programs and are also employed
by MutationDistiller: common.pm holds general functions used by all our programs,
database.pm governs database handling, and HTML.pm deals with HTML-related tasks.
Figure 4.1 at the end of this chapter provides a simplified overview of the data analysis
steps undertaken by MutationDistiller in this sorting and prioritisation process, which
I will explain in further detail below. Please note that I decided to split this figure
across sections of varying size to avoid interrupting logical sub-queries or loops within
the program.
4.1.1 Initialising
Before going through its program routine, MutationDistiller reads the user entries and
checks for problems and correct authentication: For instance, the script checks whether
the entered case ID is correct and whether there are any misspelled entries that cannot
be identified. At this stage, manual user entries such as HPO or WikiPathway identifiers
get trimmed to remove superfluous spaces or other symbols. If the program cannot find
any critical errors, it reads the selected variant classes (see also sections 5.1.4 and 3.2).
For each variant selection combination, a new comphet_ID_VARSEL table is generated,
if it does not exist already from a previous analysis with the exact same settings for
MutationDistiller: Prioritisation 54
both variants (in cases of compound heterozygosity). This table contains all genes with
at least two heterozygous variants fulfilling the variant-class criteria. For example, if
a user chose a strict setting for the first variant (only ClinVar or nonsense-mutations)
and a lenient setting for the second variant (all variants), the comphet_ID_VARSEL
table for this analysis will include all genes that contain at least two variants fulfilling
these criteria. At this step of the algorithm, MutationDistiller assesses whether the table
exists for the current settings already. If not, it is generated now and committed to the
database.
In the next step MutationDistiller queries its database for all project-specific variants (via
the unique project ID) and pathogenicity predictions obtained by MutationTaster. As
displayed in figure 4.1, this is achieved by combining information from various database
tables:
The comphet_ID_VARSEL table will be linked – i.e. form a relation – with other
project-specific (Input_ID) and global tables (all_vars and all_results) to allow Muta-
tionDistiller to receive all variants and MT results relevant for this specific analysis. In
this process, all variants that do not pass a region or candidate gene filter will not be
called from the database. For example, if candidate genes are provided, MutationDistiller
will only call variants located in those genes.
MutationDistiller’s variant selection filter (see 5.1.4 for details) allows users to focus their
attention on a subgroup of variants depending on the predicted effect they have on the
resulting protein. This filter is applied in the next step of MutationDistiller’s algorithm
and removes all variants from further processing that do not fulfil the given criteria. For
instance, if a user decided to only include variants listed as ’pathogenic’ in the ClinVar
database and/or that cause a nonsense mutation, all other alterations will be removed
at this stage.
If the user selected to filter for recessive mode of inheritance, all alterations with a het-
erozygous genotype are removed unless their harbouring genes are found in the respective
table for compound heterozgous variants. In this way, MutationDistiller trims the candi-
date list to only those variants that the user considered to be of interest for their specific
case.
4.1.2 Gene information
MutationDistiller then initialises its scoring and prioritisation protocol: First, the pro-
gram assesses each gene containing a variant that has not been excluded in the filtering
steps, and queries gene-specific information for scoring and prioritising the candidates.
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For all retrieved genes, the respective data is gathered from the database via gene iden-
tifiers provided by NCBI and Ensembl to access the data for every gene of interest. The
sources for this data are described in section 2.3.
Next, MutationDistiller reads the user’s additional phenotype entries (such as HPO terms
or GO identifiers) to retrieve additional gene information from the database and to select
relevant data for scoring and display: On the input page, users can select specific areas
or search domains to be excluded from display (e.g. OMIM reports). If any domain
is neither needed for prioritisation nor set to be displayed, it is removed at this stage.
For all other search domains, MutationDistiller checks whether a match score is to be
allocated (e.g. HPO match) and adds these scores up to receive a final MutationDistiller
score for each gene. MutationDistiller’s scoring system is explained in further detail
in the following section 4.1.2.1. The different types of gene information included in
MutationDistiller are listed in table 4.1.
In a second step, the program filters genes out that the user decided to exclude in addition
to the region filters mentioned above. This can also be the case for genes that are not
expressed in a tissue of interest, or for genes linked with a given HPO term that the user
excluded from their search. For each gene not passing the filter, a flag (dont_show) is
set to remove it from the output – thus, although these genes will be called from the
database, they will not be displayed to the user in the end.
type description
gene type describes the type of gene (e.g. protein coding)
reported mutations known mutations located in the gene
pathways KEGG pathways, WikiPathways, Reactome pathways
phenotype HPO, OMIM, OrphaNet, MGD entries for the gene
generifs short summary statements
gene function Gene Ontology entries
transcripts known Ensembl transcripts
interactions STRING protein interactions
mitochondria MitoCarta, Maestro, MitoPred entries
protein information InterPro domains, NCBI paralogs, PFAM protein families
expression ExpressionAtlas data
Table 4.1: MutationDistiller gene information. Lists information provided for
each gene.
MutationDistiller uses all gene information to generate a score, which forms the base for
its prioritisation. I describe the scoring system for the different search domains below,
with a focus on the HPO score.
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4.1.2.1 MutationDistiller score
MutationDistiller’s score embodies how well a gene and its contained variants match the
user-defined criteria. Depending on what sort of data was entered, it can be comprised
of a number of sub-scores linked with various domains of interest such as ’HPO’, ’OMIM’
and ’Reactome’. These search domains are allocated different weights based on biological
and functional considerations and mirror the quality of a match.
Some domains are given a much greater weight than others, mirroring their biological
or functional relevance. For instance, OMIM entries receive a high weight as we assume
the existence of a secured diagnosis to be a strong indicator for a gene’s relevance.
For pathway data, if a user entered information that scores several matches within one
pathway, the weight gets adjusted to avoid weighing it too heavily. For example, the
initial weight for matching a Reactome term is 5, but for subsequent matches this is
lowered to 3. In addition, to ensure that known harmful variants are ranked highly,
a ClinVar score is added to the final score if a variant is known to be disease causing
(independent of user entries). A list of the various domains and their current weights










mode of inheritance (MoI) 5






Table 4.2: Weight categories overview. Displays weights assigned to the different
categories used for scoring. Please note that for Reactome and WikiPathways, marked
with an asterisk, consecutive matches are allocated a lower weight of 3.
4.1.2.2 Scoring HPO matches
Due to their systematic nature, ontologies allow us to express and quantify the impor-
tance of a term in comparison to other terms (see section 1.4.1.5 for details). Therefore,
we were able to develop a dynamic scoring system for HPO matches: Direct matches
get scored depending on their information content, i.e. their relevance for the user. The
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more precise a HPO term is, the fewer genes will be annotated with it. An example is
the HPO-term HP:0004940, Generalized arterial calcification, which is linked with the
specific OMIM entry OMIM:208000 and only one gene (ENPP1 ). Thus, it is a very
precise term which carries a high amount of information. If such a specific term is en-
tered by a user and finds a match for a gene found in the submitted variants file, it is
quite likely that a deleterious variant is relevant in the given case. MutationDistiller will
honour this with a high HPO score:
As described in 1.4.1.5, information theory allows us to express a node’s specificity as
the fraction of annotated terms for it. In the HPO, this can be seen as the number of
genes annotated with a given term. Its information content can thus be determined as
follows:
IC(t) = −log(g(t)/g),
where IC(t) is the information content of a specific HPO term, g(t) is the number of
genes annotated with it and g is the total number of genes annotated with any HPO
term (currently 3526). For performance reasons, we have encoded this as
IC(t) = log(g/g(t)),
which is the same mathematically speaking. The result of this expression is higher, the
lower g(t) is and thus accounts for term specificity.
As phenotyping is a highly subjective process, there is always a degree of uncertainty
involved. Therefore, scoring not only direct matches but also related terms enables us to
minimise losses due to this phenotyping uncertainty. We thus decided to score ancestors
and descendants as well, but with a weight accounting for phenotyping gaps and errors:
HPOscore = IC(t) ∗ weight.
The weight for scoring HPO terms was set and optimised on clinical data as described in
section 7.1. If a HPO term is matched both directly and via an ancestor, only the direct
match is counted, and if several descendant or ancestor terms match, only the highest
score is counted.
It has to be noted that the HPO’s coverage is not uniform across the entire ontology.
Different areas within the HPO are covered with various degrees of depth due to the na-
ture of its generation – parts that are better annotated and thus have better phenotyping
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accuracy and depth are more reliable and detailed than others. Therefore, the different
branches of the HPO cannot be compared easily with each other, rendering the distance
between two terms meaningless when assessing the quality of a match. We therefore
decided not to take the distance between two terms into account when determining its
importance for scoring but instead focused on term specificity as described above.
4.1.3 Output generation
After scoring all relevant genes, the program sorts the results according to the score and
prepares the output page, limited to the number of display genes specified by the user
(default 10). We chose this default because in our test we found that MutationDistiller
was capable of ranking the vast majority of disease-relevant genes (82.2%) within the
first 10 ranks (see section 7.2.3 for details).
For each gene, MutationDistiller generates an entry in the summary table at the top
of the page. This table contains all the variants located in the gene (after filtering for
severity, position, and genotype), their MutationDistiller score, and basic gene or variant
information. Below this, detailed information is listed for each gene: To allow clinicians
and researchers to see background information on their patient’s variants at a glance,
MutationDistiller provides comprehensive information for each gene. This information is
displayed even if it is not used for scoring or prioritising or in cases where the user only
provides the variant data without any further selections or restrictions. MutationDistiller
uses NCBI and Ensembl gene identifiers to access the gene-specific data. The layout and
setup of the user interface including the output page is described in detail in the following
chapter.
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Figure 4.1: Simplified view of MutationDistiller’s prioritisation workflow,
part 1. chr: chromosome, pos: position, ref/alt: reference/alternative allele, cov:
coverage, DB: database, MT: MutationTaster.
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Figure 4.1: Simplified view of MutationDistiller’s prioritisation workflow,
part 2. chr: chromosome, pos: position, ref/alt: reference/alternative allele, cov:
coverage, DB: database, MT: MutationTaster.
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Figure 4.1: Simplified view of MutationDistiller’s prioritisation workflow,
part 3. chr: chromosome, pos: position, ref/alt: reference/alternative allele, cov:
coverage, DB: database, MT: MutationTaster.
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Figure 4.1: Simplified view of MutationDistiller’s prioritisation workflow,
part 4. chr: chromosome, pos: position, ref/alt: reference/alternative allele, cov:
coverage, DB: database, MT: MutationTaster.
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5 MutationDistiller: User interface
5.1 Input and output pages
5.1.1 Landing page
The first screen users are presented with when opening MutationDistiller at
https://www.mutationdistiller.org is our landing page that allows them to select
whether they wish to a) upload a new VCF file or b) access a previous project through
one of our user modes. We organised the landing page in a simple design consisting of
clickable bricks to allow easy access to MutationDistiller. Figure 5.1 shows a screenshot
of the landing page.
Figure 5.1: Screenshot of MutationDistiller’s landing page. This page is the
first page users see when calling MutationDistiller and prompts users to either upload
a file or to access a previous project.
5.1.2 Query Engine user interface
When clicking on the file upload hyperlink, the user will be redirected to MutationDis-
tiller’s QE (described in chapter 3). On the QE page, users can upload their project’s
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VCF file, enter additional information and pre-filter their variants to speed up the upload
process:
Project name: A project name can be allocated to make the management of several
projects easier.
Email address: As upload and analysis might take a short amount of time, we recom-
mend entering an email address. We will send a notification with a project ID for the
convenient retrieval of the submitted project at a later time. However, this information
is not mandatory as we wish to provide the option for users to remain anonymous.
Filtering: The user can decide which types of variants they wish to analyse. Heterozy-
gous variants can be excluded, which might be useful in recessive disorders, especially
in consanguineous families. In addition, low-coverage variants may be discarded and
polymorphisms stored in the 1000G or ExAC database may be excluded depending on
their genotype: By default, variants appearing 4 times in 1000G or 10 times in ExAC in
a homozygous state are removed.
Analysis settings: The analysis can include the entire VCF file or be restricted to a
certain chromosome, region, or to only exons and flanking regions. This feature is aimed
at users who have already determined a candidate region via homozygosity mapping, for
instance. In addition, users can exclude given areas from analysis to speed up the pro-
cess. However, as file upload and initial analysis only need a few minutes, we encourage
users to upload their entire file and apply region or candidate gene filters at later stages.
Figure 5.2 shows a screenshot of MutationDistiller’s upload page.
Figure 5.2: Screenshot of MutationDistiller’s Query Engine upload page.
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5.1.3 User modes
The user modes cater for clinicians, human geneticists and researchers coming from
different backgrounds, and determine which parts of MutationDistiller’s query interface
will be displayed. With each user mode selected from the landing page (figure 5.1),
different parts of the the query interface will be shown or hidden:
The query interface page is built from HTML elements called divs. By clicking on a link
within the page, the visibility setting for a div is changed from hidden to visible, and the
content of the div is displayed to the user. Similarly, when selecting a specific user mode
by clicking on one of the clickable bricks from the landing page, the visibility settings for
the different interface sections are set to display the relevant areas of the website while
hiding others. In addition, MutationDistiller creates hyperlinks to a user’s project and
their settings, allowing them to re-load their analysis with all their entries and settings.
For clinicians with a clear idea of their patient’s phenotype, the Phenotype mode dis-
plays the project section together with the phenotype section. Gene Panels displays
the project section and the candidate genes, regions, or panels section and is aimed at
human geneticists or clinicians with an idea of promising candidate genes. The Func-
tional mode shows the gene function section containing GO data as well as pathways,
whereas Expression opens the gene expression panel.
The user modes are meant to support first-time users who might be overwhelmed by the
many options offered by MutationDistiller. However, users do not restrict themselves
by selecting one of the modes - all hidden options can easily be displayed, added and
selected with one click as described above.
5.1.4 Query interface
The query interface is where the user can add their project-specific information and
criteria in order to best rank the submitted variants according to the patient’s disease
phenotype. Depending on the selected user mode, different parts of the website will be
displayed, hidden or pre-selected as described above. Figure 5.3 displays a screenshot
of MutationDistiller’s main page in the Phenotype mode (see section 5.1.3). This page
is generated by a Perl CGI script, which employs the module HTML::Template to dy-
namically fill a HTML template with values from our database (such as expression data
sources), add user entries, and check or uncheck HTML checkboxes depending on user
settings.
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Figure 5.3: Screenshot of MutationDistiller’s query interface. MutationDis-
tiller’s query interface in phenotype mode, displaying the project and phenotype sec-
tions.
The only mandatory information for the program is a MutationDistiller ID plus access
code, which was allocated by the Query Engine. This is sufficient to display the most
harmful variants in the file. However, a wide range of options are available to sort the
data. We organised these options in a number of sections:
Project
In this section, the project ID is entered. As described before, we decided to allow project
access only via the ID plus security code (rather than the name) to ensure unique access
– while several users might allocate the same name to their projects, the ID is unique
for each case. In addition, the access code ensures privacy and data protection.
The project section also provides the option to select a mode of inheritance and a maxi-
mum number of genes to be displayed in the output. Depending on their case, users can
filter genes out which do not match the indicated mode of inheritance (strict setting) or
decide to simply rank matching genes higher.
Variant Selection
For further refinement, users can select which variants they wish to have considered
in their analysis. By default, we include variants labelled ‘pathogenic’ in the ClinVar
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database, together with frame-shift mutations or nonsense variants leading to a pre-
mature stop-codon, and variants inducing amino acid changes that were designated as
disease mutations by MutationTaster. In this selection, we also include variants located
within a splice site. In addition, users can decide to include alterations considered dis-
ease causing by MutationTaster that are located near a splice site (+/- 10 base pairs),
or display all variants predicted to be disease causing. Users can also view all variants
in the VCF file, but for performance reasons we only permit this option if the analysis
is restricted to a gene region or candidate genes.
By checking a HTML checkbox, simple and complex amino acid variants considered to
be harmless by MutationTaster can be included (while excluding known polymorphisms
from databases). This setting might be especially useful when recessive inheritance
is suspected but only one strong heterozygous candidate mutation is found. In the
case of compound heterozygosity, all variant settings can be made separately for the
second variant, thus allowing a strict filter for one variant and a more lenient one for
the second. Figure 5.4 shows the query interface’s variant selection. The choices a
user makes here determine whether a new table for compound heterozygosity (table
comphet_ID_VARSEL) needs to be generated in the prioritisation protocol as described
in section 4.1.1
Figure 5.4: Screenshot of MutationDistiller’s variant selection. This figure
shows MutationDistiller’s variant selection section with the selection option for com-
pound heterozygous variants displayed.
Candidate Genes, Regions, or Panels
This section allows users to restrict the analysis to promising candidate genes. These
can be entered manually as a gene list or by region. Moreover, we offer a number of gene
panels to be selected here. Several panels can be selected at once to increase the search
radius across multiple panels. More information on the included gene panels can be
found in the introduction in section 1.4.1.4. The panel resources are loaded dynamically
from our database before the page is displayed.
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Phenotype and Gene Function
In these two sections, users can enter identifiers that link to various data sources con-
cerning phenotype information (HPO, OMIM and OrphaNet) or gene function (GO,
WikiPathways and Reactome) in auto-completion fields viaAJAX (Asynchronous JavaScript
and XML). After typing the first four letters of a symptom or disorder, the auto-
completion list is loaded and allows users to select the relevant term. The search becomes
more precise by entering more letters. Several terms might be clicked at once from the list.
In addition, specific non-relevant HPO terms can also be entered via auto-completion in
a separate field. Genes linked with these terms are then excluded from analysis. More-
over, highlighting options allow users to decide which MGD disease groups should be
stressed in the output.
Expression
Expression data sets obtained from ExpressionAtlas can be picked in this section. These
sets can be selected by developmental status (adult or fetal) or experiment (RNAseq,
protein expression or RNA-CAGE). Like the virtual gene panels, the expression resources
are loaded dynamically before the page is displayed.
Users can decide if they wish to use the data for filtering, and whether they wish to see
expression levels displayed. Data on expression levels are, however, only shown on request
to keep the output as lean as possible. If a user decides to display the expression levels,
it is denoted whether the expression of a given gene in a tissue of interest is high (within
the 75th percentile) or very high (within the 90th percentile). Please refer to section
2.2.5.2 for further details on how we integrated expression data into MutationDistiller.
If the filtering option is selected, genes that are expressed below median in a tissue of
interest are not displayed. In this case, candidate genes will only be included in the
result list if there is clear data in one of the selected data sources indicating that it is
indeed expressed in the given tissue: For example, consider a case where the clinician
expects the candidate gene to be expressed in the kidney and decides to only have a look
at genes which are clearly expressed in this tissue. MutationDistiller will now remove all
genes that are expressed below the median, but also those genes for which no expression
data for the kidney is available.
We decided on this restrictive approach to enable convenient filtering, as more lenient
filters might possibly still flood the user with too many candidate genes. In our docu-
mentation, we explain this feature and recommend to remove the filter (and instead use
expression data for display) if a user finds it too restrictive.
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5.1.5 Output page
MutationDistiller uses all submitted data entered in the sections described above to
distil the most fitting variants from the sea of candidates. The steps it undertakes to do
this are described in chapter 4. After these steps of filtering, scoring, and sorting have
been concluded, MutationDistiller generates a comprehensive output page. This page is
divided into three main sections: At the top of the page, a short list reminds the user
of their submitted entries. Directly below, a summary table lists crucial data for the
resulting variant and gene data. Further down the page, detailed information is listed
for each candidate gene. Figure 5.5 shows the user entry list and the summary table,
while figure 5.6 displays the gene details.
If only a VCF file was submitted without any further user-defined information, the
variants appear in random order, with known disease mutations on top. In all other cases,
MutationDistiller displays its data following user instructions: Variants not located in a
candidate gene or not scored will be excluded, while the order of all other variants and
their genes is determined by MutationDistiller’s score.
In the summary table, basic gene information (gene symbol and title) is listed together
with reported diseases and mutations. In addition, the overall MutationDistiller score
and its percentage of the maximum score reached in the analysis are shown as well as
some basic information on variants found in the gene. For each variant, its genomic
location and coverage in the submitted VCF file, its genotype, its predicted effect(s)
on the amino acid sequence and whether it is a known disease mutation are indicated.
Moreover, frequencies in 1000G, dbSNP, and ExAC are listed. Details about the variants’
effects can be studied with a hyperlink to MutationTaster’s results page for each variant.
Basic information from the result table can be exported for external storage and further
downstream applications. Figure 5.5 provides a screenshot of an example result table.
Below the result table, MutationDistiller lists more in-depth information on each candi-
date gene. This information can be accessed by scrolling down or by clicking on the gene
symbol in the result table. Here, the user is not only presented with the MutationDis-
tiller score and its composition, but also with detailed up-to-date data on the gene of
interest. Moreover, hyperlinks provide access to external sources, allowing users to assess
the relevance of a gene with ease.
The data sources used for providing detailed gene information are explained in chapter
2. In the output page, we group these sources in logical sections: First, general data
such as ClinVar, Modes of Inheritance, and relevant links are listed. Here, we indicate
the overall MutationDistiller score together with this sub-scores. In the next section,
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Figure 5.5: Screenshot of MutationDistiller’s result table. This figure shows
the result table for a HPO-based example project.
pathway data and protein information are listed. If a pathway receives a match, this
term will be scored and highlighted in bold. The following section provides information
on symptoms and diseases: For HPO, all terms linked with the gene are listed. Direct,
ancestor or descendant matches are highlighted and their score is indicated. For OMIM,
GO and Orphanet, we list all entries for the gene highlight matches. Finally, we list
Ensembl transcripts with hyperlinks to the relevant Ensembl webpage. If a user selected
to display additional information (such as expression data), we list these data below.
Figure 5.6 provides a screenshot of the detailed gene view.
Figure 5.6: Screenshot of MutationDistiller’s detailed view. The detailed view
provides an insight into MutationDistiller’s scoring system together with in-depth data
for every candidate gene.
To enable flexible analyses, the program also allows for interactive refinement of the
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search: A hyperlink takes the user back to the entry page but keeps the previously
entered terms and selections. This hyperlink can be bookmarked to resume the analysis
later and to exchange prioritisation settings with colleagues. Moreover, HPO terms can
be added or excluded flexibly without having to re-load the entry page. Both features are
achieved using CGI scripts that hand the selected values and properties to the relevant
scripts for the generation of the interface.
5.2 Manual and tutorial pages
In order to make it as easy as possible for users to start working with MutationDistiller,
the tool comes with extensive documentation and tutorial pages. On these pages, we
explain how to get started with MutationDistiller and provide information on updates
and changes. The tutorial is a step-by-step analysis of an example case, which is intended
to get users acquainted with MutationDistiller’s many options. The tutorial can be found
at https://mutationdistiller.org/info/tutorial.html, the manual is located at
https://mutationdistiller.org/info/documentation.html. Both can be accessed
easily at any stage through hyperlinks.
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6 Implementation and Tools
6.1 Software development
We developed MutationDistiller in an iterative fashion: Instead of following a detailed
plan, we took user input and newly emerged data sources into account during each step
of software development. In this way, we ensured that the resulting program would be
up-to-date and easily accessible for the intended users.
6.1.1 MutationDistiller
The program and functions of MutationDistiller were written in the programming lan-
guage Perl. Central modules – collections of functions – contain all the relevant sub-
routines, grouped by their purpose for the program. A number of freely available Perl
modules were incorporated into the program, which we obtained via the operating sys-





















The MutationDistiller QueryEngine (QE) was written in Perl as well. Job scheduling
is handled by the TORQUE Resource Manager2. The single Perl scripts that make
up MutationDistiller’s QE are called via shell scripts. The user submissions entered in
the start page are being read out using the Perl module CGI, the communication with
TORQUE is handled by the Perl module PBS::Client.
6.2 Manuscript
The Entity Relationship Diagrams (figure 2.3 and Appendix C) displayed in this the-
sis were generated with the great, freely available database tool DBeaver (https://
dbeaver.io/, accessed 28.12.2018). I conducted statistical analyses, designed plots and
printed appendix tables using the programming language R (version 3.4.3) [113] and
its packages plyr [114], dplyr [115], xtable [116], ggplot2 [117] and reshape [118]. The
flowcharts describing the workflow of MutationDistiller’s prioritisation algorithm and
its Query Engine (figures 4.1 and 3.1) were generated with the freely available online
diagram software draw.io (https://www.draw.io/, accessed 12.06.2019).
6.3 Hardware
All MutationDistiller applications run on a 48-CPU system with 512 GB RAM under
Linux (CentOS 6). All program scripts are written in Perl (5.10) and run in an Apache
2.2 web server with modperl2. User interfaces are written in HTML with JavaScript
functions. The database is run on PostgreSQL 9.5.
2http://www.adaptivecomputing.com/products/open-%20source/torque/, accessed 20.12.2018
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7 MutationDistiller: Optimisation and valida-
tion
7.1 Determination of HPO weights
7.1.1 Training Data
We built MutationDistiller to find the most likely disease causing candidate(s) from a
sea of potentially harmful alterations. In this endeavour, the tool will be faced with
a large variety of genetic variants, which may be linked with many different diseases
or phenotypes. To get MutationDistiller up and ready for the task, we trained and
optimised its HPO score and weights using information that represents and resembles
the data it will encounter in real-life cases.
As real patient data and disease-gene connections are hard to come by or not available
due to data protection issues, current variant prioritisation tools have have usually been
trained and optimised using somewhat artificial data sets. For example, PhenIX [75]
was developed and tested by randomly selecting HPO terms from the list of HPO terms
annotated for a gene of interest. eXtasy [71], on the other hand, used gene-phenotype
associations generated by the tool Phenomizer [119], a procedure that guarantees ideal
associations which do not usually occur in clinical day-to-day life.
We have optimised the matching procedure of HPO terms by choosing an approach
that attempts to be as realistic as possible while still accounting for data and patient
protection: The variant database ClinVar [44] contains a range of disease mutations
with HPO identifiers as associated phenotype information. These identifiers have been
submitted by users – mainly clinicians and researchers – and thus can be expected to
resemble a real-life situation more closely than artificial data. Moreover, ClinVar data
covers a relatively wide range of different diseases and gene groups, thus enabling to
represent various medical fields. We obtained all ClinVar entries with at least two HPO
terms that were labelled as pathogenic. In total, we were able to compile a set of 188
cases linked with 142 different genes. We then integrated the ClinVar alterations into a
freely available 1000G exome VCF file (HG00377) and sent the resulting VCF files to
MutationDistiller in order to optimise the HPO scoring system.
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7.1.2 HPO weight parameter selection
As described in section 4.1.2.2, the ontology structure of the HPO allows us to base the
HPO scoring on information content. In addition, we can not only score direct matches,
but also ancestor and descendant terms. This helps to account for phenotyping errors
and gaps: If a user enters a certain term for which a gene is not directly annotated,
it would not be scored at all, even if the first descendant is annotated. Therefore, we
devised a system that scores direct matches, but also ancestors and descendants. In order
to evaluate in which way they should be weighted against each other to reach optimal
results, we used the ClinVar-set described above to iterate through a range of weight
combinations (245 combinations in total) between the three categories (direct matches,
ancestors, descendants). We chose this approach rather than dynamically searching for
the optimal weight distribution to avoid overfitting on this relatively small data set.
Table 7.1 shows the different weights we combined for the three categories. We then
recorded the ranks given to the genes containing the indicative alteration and only re-
garded the first 100 ranks, labelling any cases beyond that as ’not found’. Genes with
the exact same score were given the same rank – this means that for each case, usually
more than 100 genes were included in the analysis.
HPO match type weight
direct 0.2, 0.5, 1, 2, 5
ancestor/descendant 0, 0.05, 0.1, 0.2, 0.5, 1, 2
Table 7.1: HPO optimisation weights. Displays the different weights tested for
direct, ancestor and descendant hits.
For all cases in which the disease mutation was found, we then observed the rank distri-
bution for the disease genes across all weight combinations. We only regarded the first
100 ranks, denoting any cases beyond that as ’not found’. Genes with the exact same
score were given the same rank. For each combination, we evaluated how many indicated
disease genes were ranked on rank 1, ranks 1 to 5, greater than 10, or not found at all.
We also calculated the mean rank for all disease genes across each combination.
We found that, for each of the various weight-combinations, a relatively high number
of of cases (at least 22.3%) could not be solved, indicating that the phenotypes en-
tered into ClinVar are not always identical to the phenotypes associated with the disease
genes. This is consistent with a real-life situation in the clinic with phenotyping errors
and inconsistencies. In addition, it was evident that a high weight for direct hits was
consistently better at ranking the alteration of interest amongst the top positions.
We then assessed the resulting weight-combinations under specific considerations to find
the best suited solution:
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a) Balanced for direct hits, ancestors and descendants: To represent all three
categories in the weighting process, we excluded all candidates with zero-scores in one
of the categories, but included small values (0.05 at the lowest).
b) Able to detect the causative variant: We only included combinations for closer
consideration that were able to find the disease-relevant gene in the majority of cases.
As mentioned above, a high fraction of cases (minimum 22.3%) were not found within
the top 100 in any of the weight combinations.
c) Low mean rank: To ensure that the gene of interest frequently shows up in the
top ranks, we excluded combinations with a high mean rank across all disease-relevant
genes.
d) Causative variants on rank 1: In addition, we ensured that a large proportion of
the genes of interest get ranked on top.
Together, we expect these criteria to ensure that MutationDistiller is capable of ranking
the most likely candidate genes within the top ranks for a majority of the cases the
program encounters. After careful consideration, we decided on a weight of 5 for direct
hits, 0.05 for descendants and 2 for ancestors as this combination showed a comparatively
low loss-rate (22.8%) while ranking the indicative genes on the top rank in 37.2% of the
cases. In addition, it reached a low mean rank for the genes of interest (5.82). We
then incorporated this combination into MutationDistiller and used this version of the
program for further testing and comparison with other tools (see below). We also found
that while the loss rate was relatively high to begin with, in the groups with the lowest
mean rank for the indicative genes it did not change much – it was always around 23%.
This indicates that the loss rate is not linked with the weighting but with the phenotyping
or the HPO annotation process itself.
Table 7.2 shows the parameters of the weight-combinations with the lowest loss rate. A
summary of all tested combinations can be found in table A.1 in the appendix.
weights indicated disease mutation
direct hit ancestor descendant top rank top 3 not found mean rank
1 2 0.5 0.04 0.25 0.223 9.5
0.2 0.5 0.1 0.03 0.21 0.223 10.1
0.2 1 0.1 0.02 0.21 0.223 11.5
0.2 2 0.1 0.02 0.13 0.223 11.9
5 0.05 2 0.37 0.5 0.228 5.8
Table 7.2: HPO weight iterations. Displays the top iterations for direct hits,
ancestor and descendant weights by minimal drop-out rate (not found: disease mutation
not listed within the first 100 ranks) for the ClinVar-HPO set.
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7.2 Testing and validation
7.2.1 Test set
To test how MutationDistiller would fare in a real-life scenario, we compiled a test set of
101 existing patient cases from Charité Berlin. These cases of rare, early onset genetic
disorders were provided by clinicians and researchers working in the Neuropaediatrics
and the Medical Genetics departments. The patient had given consent for research use
The clinicians provided patient VCF files together with the causative variant(s) and the
relevant genes, the HPO terms that were used in the quest to find the disease-relevant
alteration, and information on the expected mode of inheritance (if available). We en-
sured that there was no overlap between the ClinVar cases used for program optimisation
and the validation data set.
We had originally planned to compare MutationDistiller with online versions of other
tools. To account for patient data protection, we hence spiked the known causative vari-
ant for each case into the same 1000G VCF file used for optimisation of MutationDistiller
(HG00377). Due to performance reasons, however, we had to rely on downloaded versions
of the program.
7.2.2 Validation
We sent the resulting VCF files containing the disease mutation(s), the HPO identifiers
and mode of inheritance information submitted by the clinicians to MutationDistiller
to validate its performance on this real-life data set. For the test, we used the weight
settings determined in the optimisation step. For the mode of inheritance, we chose
the same weight as for a direct HPO match (5) to avoid it being underrepresented.
The goal for this test was to determine MutationDistiller’s capabilities for detecting
disease-relevant alterations in a HPO-centric search and to compare them with other
state-of-the-art tools. In MutationDistiller, known pathogenic variants from the ClinVar
database are given a ClinVar match score as described in 4.1.2. However, the tools
included into this comparison do not provide this function. We therefore decided to not
allocate MutationDistiller’s ClinVar score at this stage. However, this means that in real
life, the MutationDistiller results can be expected to be slightly better for known disease
mutations.
We then observed which rank the gene containing the known disease-relevant alteration
was given by the program. As in the optimisation step, we only regarded the first 100
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ranks, labelling cases where the gene of interest could not be located within these ranks
as ’not found’. For genes that obtained the exact same score, we allocated the same rank.
We found that MutationDistiller was capable of finding all but one of the disease-relevant
genes within the first 100 ranks. In total, MutationDistiller reached a mean rank of 6.52
for the indicative gene across the test set. In the vast majority of cases, the disease gene
indicated by the clinicians was ranked within the first 10 ranks (82.2%). Table 7.3 shows
the number of disease genes ranked within ranks 1 to 10 for the set of 101 cases.











Table 7.3: Validation set ranks. Shows the first 10 ranks for the validation set as
absolute and cumulative numbers. If several genes reach the same rank, they are all
allocated the best rank. Total number of cases: 101.
As can be seen in this table, over half of the indicated disease genes were ranked within
the first 3 ranks by MutationDistiller, and over two-thirds were ranked within the first
five ranks. The distribution across all ranks from 1 to 100 is depicted in figure 7.1.
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Figure 7.1: MutationDistiller rank distribution for the validation set. Dis-
plays the rank distribution (in percentage) for the indicated disease genes in the val-
idation data set. The cumulative distribution can be found in the following figure,
7.2.
7.2.3 Comparison with state-of-the-art prioritisation tools
To assess MutationDistiller’s performance in comparison to other, frequently used variant
prioritisation tools, we decided to send the validation data set to a number of similar
programs. We included algorithms into our test that are freely available online and do
not require any software installation or user login (to avoid data security issues). In
addition, we only included tools that can work with VCF files and offer HPO-centric
prioritisation. We also excluded candidates such as Phen-Gen [72], which requires trio
VCFs (usually data from unaffected parents and an affected child) as this would have
substantially reduced the potential test cases. Moreover, we had to remove a number of
tools that unfortunately were not functioning at the time of testing.
We were thus able to compare MutationDistiller to three different algorithms, the PhenIX
[75] and HiPhive [120] algorithms incorporated into Exomiser [121] as well as eXtasy [71].
We used Exomiser version exomiser-cli-10.0.1 and the eXtasy version 2013-07-04 (the
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latest version available from their GitHub page1. We stuck to default settings, which is
what an untrained user is expected to do. For each of these algorithms, we had to rely
on locally installed versions as the online tools were not working reliably or fast enough
for our purposes.
The Exomiser generates a number of different scores, the case-relevance of which is not
easily obvious to users from the clinic. Hence, we decided to limit our assessment to the
so-called ’Exomiser gene pheno score’, which we deemed to be most fitting to the task at
hand, namely the matching of genes to phenotype data. As the eXtasy algorithm is not
capable of working with all HPO terms, for this tool we removed the terms not found in
eXtasy’s database from our set. This limited our eXtasy analysis to 88 cases. Moreover,
eXtasy’s entry options are limited to 10 HPO terms per case. We thus randomly removed
all terms exceeding 10 from the 7 cases where this was necessary.
To assess and compare the capabilities of the different algorithms, we sent the validation
set (VCF files, HPO annotations and mode of inheritance information, if available) to
them and recorded, for each case, the rank of the indicated disease gene. For eXtasy, we
had to distinguish between cases in which only one HPO term was used for analysis and
cases with more than one term. In single HPO cases, we ranked the files by ordering
them by the result score; in combined cases we ranked them by the provided statistical
score as the program outputs a result score for each HPO term separately.
We then examined which proportion of cases were ranked at which position and com-
pared the outcomes between the different programs. To ensure that the results from the
various algorithms can be compared, we also capped the search at rank 100, as for the
MutationDistiller test. Cases in which the gene of interest was not located within the
first 100 ranks we hence considered to not have been solved.
When comparing the cumulative ranks allocated to the disease genes, we found that
eXtasy failed in a large majority of the provided cases. To start with, due to the lack of
HPO terms in its database, the analysis was limited to 88 cases of the 101 test cases. Of
these cases, eXtasy found less than 30% of the causative alterations within the first 100
ranks, which might be due to the fact that the underlying gene-phenotype associations
were updated more than 5 years ago.
For HiPhive and PhenIX, we found that those algorithms were capable of detecting the
causative gene within the top 100 positions in the majority of cases. However, Muta-
tionDistiller was capable of solving considerably more cases than the other tools (99% for
MutationDistiller, 81.2 % for PhenIX and HiPhive). This was shown to be the same for
genes of interest that were ranked within the first 10 (82.2% for MutationDistiller, 68.3%
1https://github.com/asifrim/eXtasy/blob/master/README, accessed Aug 2018)
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for PhenIX, 63.3% for HiPhive) or 20 positions (94.1% for MutationDistiller, 73.3% for
HiPhive, 70.3% for PhenIX). Figure 7.2 displays the accuracy of the tested tools as the
cumulative percentage of indicated disease genes ranked within each rank group from top
1 to top 100. To obtain this figure, we calculated the cumulative percentage of correct
disease genes ranked within each group (on the first rank, within the first two, three,
four, and so on) and plotted the distribution up to rank 100 for each of the four tested
tools.
Figure 7.2: Tool Comparison: Cumulative rank frequencies. Cumulative rank
frequencies for the HPO-based detection of disease mutations in a set of 101 patient files
for MutationDistiller (black), PhenIX (orange), HiPhive (blue) and eXtasy (red). For
each tool, the accuracy is depicted as the cumulative percentage of indicated disease
genes sorted within each rank group (top 1 to top 100). Published in Hombach D et al.
MutationDistiller – user-driven identification of pathogenic DNA variants. NAR Web
Server Issue. 2019. doi:10.1093/nar/gkz330
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8 Discussion
8.1 Data selection process
MutationDistiller is a tool to prioritise genetic variants based on genetic, clinical and
biological data. As such, its performance and success stand and fall with the data it bases
its decisions on. These data come in two kinds: On the one hand, the program depends
on the quality of the integrated data sources; on the other hand its scoring and sorting
success relies on the training and optimisation cases used during program development.
In addition, MutationDistiller’s performance also heavily depends on the quality of the
phenotyping, but the responsibility lies with the user and cannot be addressed by us.
In order to span a wide variety of cases and to cater to needs from different user groups,
we decided to include a wide range of data and information sources (see section 2).
We integrated up-to-date data covering a plethora of genetic fields. As some of these
sources are still based on genome version GRCh37 – which has also been used by all
groups which were involved in the development of MutationDistiller – we also decided to
base MutationDistiller on this genome build. Even though the later build GRCh38 has
been available for several years now, it has not yet completely entered the field: some
secondary data sources employed by MutationDistiller and MutationTaster, such as the
ExAC data, are based on the previous build. However, in the future, with more and
more potential users and secondary data sources migrating to the new build, we plan
to also update MutationDistiller and its databases to accommodate scientific advances
made in deciphering the human genome.
8.1.1 Integrated data types
In the following, I will discuss the main data sources and the reasoning behind choosing
them for inclusion into the program.
Phenotype data
We decided to develop MutationDistiller as a phenotype-based prioritisation tool based
on ontologies and disease repositories such as OMIM [59], OrphaNet [60] and especially
the HPO [58], as they are widely used and well-accepted in the field of human genetics.
For the HPO, this wide acceptance is mirrored by the number of HPO-based approaches
and tools that help users in the phenotyping effort, e.g. Phenomizer [119], PhenoTips
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[122], or Phenotero [123], which was developed in our group. In addition, a number of
phenotype-driven platforms such as DECIPHER [95], DDD (Deciphering Developmental
Disorders) [124] or Phenopolis [125] base their analysis on the HPO as well.
However, if a complete diagnosis is available for a patient, translating this into sets of
phenotypes (i.e. HPO terms) adds an unnecessary layer of uncertainty. In those cases,
it makes more sense and is much easier for the clinician in charge to simply choose
the relevant diagnosis for data analysis. Because we did not wish to limit our users
to HPO data, we also integrated OMIM and OrphaNet data. We expect the existence
of a secured clinical diagnosis to be of greater relevance for a case than a collection of
HPO symptoms. Thus, we allocate a much higher weight to Orphanet or OMIM entries.
However, it has to be noted that the weighting system is not set in stone and will be
updated and improved as user feedback comes in.
In addition, we also include a phenotype-genotype resource not linked with human data;
the MGD [126]. This repository stores data on phenotypes observed in mice and their
genetic background. Mice have been used as model organisms in genetic disease for a long
time. As a consequence, a large set of phenotype-genotype connections are known; more
than for humans: While the HPO contains around 12,000 genotype-phenotype relations,
The MGD stores over 300,000 mouse phenotype annotations1. This knowledge can be
particularly helpful in the discovery of unknown disease genes. The limitation to known
disease genes is one of the main drawbacks when relying on repositories such as the HPO,
OMIM or Orphanet, as it limits the number of cases that can be solved by these means.
We therefore incorporated 20 disease classes from the MGD:human disease portal into
MutationDistiller, hoping to enable the detection of new disease genes.
Together, we expect the phenotype data available on MutationDistiller to enable flexible
analyses while limiting options to the most relevant and reliable data sources.
Gene panels
While NGS methods allow the analysis of entire exomes or even genomes, they come at
a high cost: They generate large data sets of variants which all have to be considered
for further testing. One way to get around this is to apply virtual panels, which allow
users to restrict their search to certain candidate genes. This panel-based usage of NGS
data has previously been suggested as a time- and cost-effective method [101]. We thus
decided to include this option in MutationDistiller.
While incorporating commonly used panels, we decided to not allow MutationDistiller
users to deposit their user-specific panels on our servers as this would cause issues of
data privacy and usability: Either, these panels would have to be available and visible
1http://www.informatics.jax.org/, accessed 05.06.2019
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to all users, or each user would have to create an account to keep their panels safe and
secret. Therefore, instead we decided to allow users to simply upload or copy their gene
lists whenever they run an analysis.
Gene function data
While most tools with a similar aim to MutationDistiller focus their options on disease
symptoms (i.e. via the HPO), we decided to offer to search via gene function data such
as the Gene Ontology (GO), gene expression or metabolic pathways.
The GO offers comprehensive data on the function and properties of genes. By including
this resource as an option, we allow users to identify genes of disease relevance which
have not yet been identified as such. While symptom- or diagnosis-based searches (HPO,
OMIM, Orphanet) are of great importance in routine clinical cases, they do not allow
the detection of hitherto unknown disease genes (see also section 8.3).
In addition, in a number of rare diseases, only specific tissues or organs are affected.
An example is Cutis Laxa, a group of connective tissue disorders that manifest in the
skin. In those and similar cases, the search for the causative gene can be rendered
easier by limiting the search to genes that are expressed in a tissue of interest (e.g. the
skin for Cutis Laxa). While this is not yet exploited by most tools, we are convinced
that this feature can be of great help in a number of cases. We thus decided to offer
users the option to include expression information for their analysis as an alternative
method, or in addition to other data. We incorporated a number of data sets obtained
from ExpressionAtlas as this source offers curated sets while including a wide range of
experiments (see chapter 2.2.5.2 for more information).
Currently, MutationDistiller allows users to search and filter their data for genes that
are expressed in a tissue of interest. It might be conceivable, however, that users are
interested in genes that are explicitly not expressed in a given tissue, for example in the
case of promoter mutations. In the future, we are planning to include a feature into
MutationDistiller that enables users to find genes that are not expressed (or expressed
below median) in a tissue or tissue group.
Transcriptome data – data on all (m)RNA molecules present in one cell or a population
of cells – depicts the amount of gene expression that is present at a given time. It allows
us to see gene expression changes in tissues as affected by disease, enabling detailed
assessments of affected organs or systems. As disrupted gene expression is known to play
a role in rare disease [127, 128], including transcriptome data into analysis has been found
to increase diagnostic yield in rare disease [129, 130] as well. Currently, the availability
of public transcriptome data – especially linked with monogenic diseases – is limited.
Recently, however, we have observed an increase in the research on transcriptomes of
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rare disease patients [131–133] and we expect this field to grow further in the future.
Thus, with the rise relevant data sources, we are planning to include these options as
well.
Similarly to gene expression, certain pathways are known to be involved in the develop-
ment of specific rare disorders. For instance, the pentose phosphate pathway (PPP) has
recently been found to be affected in rare kidney diseases [134] while the mammalian
target of rapamycin (mTOR) pathway is a frequent target in neurodevelopmental disor-
ders [135–137]. Thus, including pathway data might improve diagnostic yield in certain
cases. We currently include three main data sources: Reactome and WikiPathway can
be used for active analyses while KEGG pathway data is displayed in the results. As
KEGG pathway information is no longer freely available, the data included into Muta-
tionDistiller is somewhat dated. We therefore decided to only display the data rather
than allowing users to actively search for KEGG pathways. In this way, clinicians have
the advantage of being able to include the latest pathways into the ranking of their can-
didate variants while at the same time having the long-standing information of KEGG
at their disposal.
The ability to include expression or pathway data directly within MutationDistiller in-
stead of having to go through the HPO can thus free users from an additional load of
work. While the HPO is currently one of the main used resources, it can be difficult to
use and cause problems due to the complex procedure of phenotyping. We are therefore
convinced that the option to not have to rely on the HPO can help many users – espe-
cially non-geneticists who suspect a genetic cause in a patient’s disease – in their daily
work.
8.1.2 Testing and training data
The second type of data shaping MutationDistiller, the cases used for training, optimis-
ing, and testing, were selected in an attempt to mirror real-life patient cases as closely as
possible. As described in chapter 7, the program’s HPO score was developed using vari-
ants with known phenotype associations obtained from ClinVar and tested using actual
patient data from the Medical Genetics and Neuropaediatrics departments at Charité.
Our rationale for this patient-centred approach was the drive to develop a tool that is
able to model real-life cases as truthfully as possible. Due to the aforementioned lack of
combined genotype and phenotype data, most other similar tools have been developed
using somewhat artificial data. PhenIX [75], for instance, was tested using modified
sets of HPO terms generated from the OMIM gene entries – which is not the same as
clinical sets with their errors and lack of exactness. Exomiser [73], on the other hand,
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was tested with curated, ’optimal’ HPO sets as obtained from HGMD. Both approaches
deviate from the real situation found in the clinic: Here, a clinician examines a patient
and then describes their symptoms in medical terms that can then be translated into
HPO identifiers.
In daily clinical routine, clinicians rarely encounter the model patient who displays all
(and only those) symptoms listed for a specific disease. In reality, the symptoms of
two patients diagnosed with the same disorder can be quite different. In addition, even
the lists of symptoms assigned to the same patient by different physicians might differ
strongly, which is what we found in several cases in our data. These problems found in
phenotyping cannot be reliably mirrored by artificial means but severely influence the
outcome of a WES analysis. We thus decided for a different approach, even though this
restricts our training and testing data to a relatively small number of cases, since, largely
due to data regulation and confidentiality issues, real patient data of disease-relevant
alterations and phenotype links is difficult or impossible to use. For MutationDistiller,
we were able to collect 188 training cases from ClinVar and 101 in-house clinical data
sets from patients who had given consent to scientific use of their data. While under the
given circumstances we considered these data sets to be large enough for our purposes,
the program’s performance could potentially be improved by adding more training or
test cases. We thus hope to be able to increase the data set sizes in the future. However,
we are convinced that the benefits of having realistic data outweigh the comparably low
number of test cases.
8.2 Scoring
8.2.1 HPO score optimisation
MutationDistiller scores and weighs variants and their genes according to user-defined
criteria and sorts them accordingly. The tool covers a wide range of information sources
and weighs the different types of data against each other. We decided on a pre-set
scoring system that cannot be altered by the user as we learned from a previous program
developed in our group, GeneDistiller [81], that allowing users to manually alter weights
can be overwhelming and alarming for new users, even if they never apply any changes.
Thus, MutationDistiller does not support this option. Instead, on the result page, the
program lists in detail which data source contributed to the score in which way. In this
way, the tool enables users to draw their own conclusions on the reliability of their scores.
For most data types, such as pathways, expression data, or MGD entries, the underlying
scores were determined by biological and clinical considerations. For instance, if an
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OMIM entry – a clinical diagnosis – has been entered and a match is found, this is
rewarded with a high score as this type of data is of great clinical relevance and hence
of importance for the user. Matching pathway data, on the other hand, is scored with
a lower score as the clinical significance of pathways cannot usually directly be deduced
from available data.
Thanks to the availability of genotype data in connection with relevant HPO terms (our
ClinVar and in-house data sets), we were able to optimise and test this scoring for HPO
entries (see section 7). For all other data types, this was not yet feasible due to a lack of
suitable data or users. All our cooperation partners thus far have based their analyses on
the HPO as well. However, over time, we hope to receive feedback from users of diverse
backgrounds, which would enable us to update MutationDistiller and to optimise the
weights for other data sources.
8.2.2 Mutation severity
In our scoring system, and in opposition to many other tools such as PhenIX and Ex-
omiser, we do not include the ’gravity’ of a variant’s predicted effect. MutationDistiller
receives its pathogenicity prediction from MutationTaster, which employs a Naïve Bayes
classifier to sort the variants into either ’harmless’ or ’harmful’. While the classifier also
delivers a probability value, this does not mirror how severe an alteration is but only
how certain the classifier is with its decision. Instead, the severity of a mutation can be
seen as its capacity to cause harm to the gene product – thus, a nonsense variant can
be expected to be more harmful than most other variants (which is indicated by Mu-
tationTaster’s disease-causing (automatic) classification). We therefore do not include
MutationTaster’s probability value into the scoring system, but allow users to investigate
a variant in detail by offering a direct hyperlink to MutationTaster’s prediction for it. In
addition, we allow users to filter variants by severity via our variant classes. Moreover,
we plan to improve and increase this functionality as described in section 8.5.6.
8.3 Phenotype data variety
8.3.1 Detection of new disease genes
The notion that diagnosis of rare diseases can be improved or accelerated through the
inclusion of phenotype data is mirrored by the number of phenotype-based analysis tools
that have been developed in recent years (see section 1.4.2). Most of these tools are based
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on the HPO, as this resource is currently the most widely used in human genetics. Thus,
we expect most of our users to be used to and to already rely on HPO-based phenotyping
data, and hence focused the development of MutationDistiller on this resource. Indeed,
most of our users to date have based their search on the HPO. However, it has to be
noted that analyses based on the HPO or resources such as OMIM and Orphanet are
only able to detect genes which are already known to be involved in the development of
genetic disorders.
However, new ways of analysing rare disease cases are needed, as the diagnostic yield
in NGS projects is usually reported to lie between 25-30% [76, 138, 139]. Reasons for
this are manifold; the disease-causing mutation might not be covered (sufficiently), or
be located outside of the coding sequence. In addition, it might not be recognised as
a disease mutation, or be located in a gene that has not yet been discovered to be
disease-relevant.
However, as described above, the inclusion of functional data, such as GO, expression
or pathway resources, allows us to detect ’new’ disease genes. This approach, which is
feasible using MutationDistiller, can thus help in elucidating currently unsolved cases.
Therefore, we expect our tool to be of assistance in a range of cases where current means
have not been able to identify the causative variant. The benefit of re-analysis of WES or
WGS data which has previously not led to success has recently been demonstrated by the
Deciphering Developmental Disorders (DDD) team in the UK [124]. MutationDistiller’s
flexibility lends itself to attempt re-analyses using new resources or with novel insights
about the disease, and we hence expect the tool to be of use in many currently unsolved
cases.
8.3.2 Symptom annotations
A lack of annotated symptoms can be a problem when relying solely on HPO-based anal-
yses. The HPO obtains symptom annotations via OMIM and Orphanet, and depending
how quickly and reliably these links are established and updated, there might be quite
some lag-time. By offering a wide range of options for entering patient-related data,
MutationDistiller can find mutations in genes that are not yet sufficiently annotated:
As an example, one of our collaborating clinicians provided whole exome data from a
patient diagnosed with congenital myasthenia suffering from areflexia (HP:0001284) and
muscular hypotonia (HP:0001252). The pathogenic variant in this case had previously
been determined to be located in the SLC5A7 gene. However, when trying to assess
this case using the HPO terms described above in MutationDistiller and other software
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tools, the causative variant could not be found within the best ranks. Despite being
listed in OMIM as a molecular cause for congenital preysnaptic myasthenic syndrome 20
(CMS20, OMIM:617143) and distal hereditary motor neuropathy type VIIA (HMN7A,
OMIM: 158580), the SLC5A7 gene was not linked with these symptoms in the HPO,
and hence the programs could establish a connection. In MutationDistiller, users can
chose one of multiple alternative approaches to overcome this obstacle: By restricting
the search to a relevant virtual panel – in this case the congenital myasthenia panel from
PanelApp – the clinician was able to identify the causative alteration. Alternative ways
to come to the same result would have been to enter the clinical diagnosis via OMIM, or
to upload an in-house virtual panel.
8.4 Comparison with state-of-the-art tools
To evaluate MutationDistiller’s ability to prioritise relevant variants, we compared its
performance to similar state-of-the art tools. As described in section 7.2.3, we decided to
limit our comparison to tools that are freely available online without any need to install
or log in. However, it has to be noted that we had to fall back to downloaded versions
of the tools as using them online would have been too slow.
We compared MutationDistiller’s prioritisation capabilities to three other algorithms,
eXtasy, PhenIX and Exomiser. In a recent comparison analysis which did not include
MutationDistiller, PhenIX was found to deliver the best results on 21 exomes [140]. This
study was conducted without the involvement of any authors of PhenIX.
Using our set of 101 variants obtained from the Charité, we found that MutationDistiller
was capable of placing the causative variant within the top 10 in over 80% of the cases,
thus out-competing the other tools included in our comparison.
However, in addition to HPO terms and in contrast to many other software options,
MutationDistiller offers a wide range of input data. Unfortunately, due to a lack of
both testing data and candidate tools, we were not able to compare MutationDistiller
quantitatively in this respect and had to limit our comparison to HPO data.
When designing MutationDistiller, we aimed to generate a comprehensive and user-
friendly software tool for clinicians and researchers. This becomes obvious when com-
paring the output and surrounding information of the four tools: MutationDistiller pro-
vides a wide range of information in the output page rather than a battery of scores. In
addition, the tool displays the final score and its contributing sub-scores to allow users
to make an educated decision about their case. Moreover, our program provides com-
prehensive tutorial and manual pages, aiming at making its its usage as easy as possible.
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We are convinced that these features facilitate MutationDistiller’s use in the clinic, as
suggested by Shyr et al [70].
It has to be noted that comparisons of multi-faceted tools such as MutationDistiller are
difficult to achieve as many different factors have to be taken into account. A realistic
comparison would have to be conducted by researchers who do not have any stakes in
any of the tested tools. In this way, one could study how much time a trained physician
spends to identify a mutation which they truly believe to be causal. Unfortunately, so
far no one volunteered for this time intensive task.
8.5 Outlook
MutationDistiller in its current form supports a wide range of input data to determine
the most likely disease-relevant alterations for a given case. Nevertheless, as in any
project, there is always room for development and improvement. For the future of
MutationDistiller, a number of development opportunities remain, which I will discuss
in the following sections.
8.5.1 Family analyses
In contrast to other means such as linkage analysis, NGS analyses are able to determine
the most likely disease-relevant alterations even if there is only the patient’s genotype
available. However, the hunt can be made much simpler when using family data by
adding data sets obtained from (healthy) relatives. The most common approach is the
analysis of trios consisting of the patient and her or his parents. In previous comparison
studies, this approach has been found to increase diagnostic yield [138, 139, 141]. More-
over, this approach has great advantages when filtering against variant databases such
as ExAC, as only the variants occurring in the family have to be taken into account and
the issue of variant frequency can be neglected.
Adding the parents’ or siblings’ sequencing information to the analysis allows the ex-
clusion of a large number of potential alterations: In recessive disorders with complete
penetrance, all alterations that can be found in a homozygous state in a healthy indi-
vidual can be safely removed from further investigation. In fully penetrant dominant
disorders, even inherited heterozygous alterations can be discarded. Thus, in dominant
modes of inheritance, de novo mutations can be specifically searched for. MutationDis-
tiller already allows the analysis of trio data in an indirect way: A user can create
separate projects and then compare the results to exclude non-relevant data. This ap-
proach, however, is rather cumbersome. Thus, we plan to update MutationDistiller to
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allow analyses of families in addition to the analysis of singletons.
We have thus far not been able to introduce this function due to a lack of training data,
as trio analyses have not yet been introduced in routine care due to the higher cost
compared to singleton sequencing. As sequencing costs drop and the awareness of the
benefits of trio analyses rise, however, a higher rate of trio analyses is to be expected
even in routine settings. This would allow for the development of suitable tools while
simultaneously increasing the demand for such software. We hence plan to add this
feature to MutationDistiller in the near future.
8.5.2 Genome version
Currently, MutationDistiller is based on genome build GRCh37, even though a more
recent version, GRCh38, has been available for a number of years. We made this decision
due to the fact that secondary data used by MutationDistiller and MutationTaster is only
available for GRCh37. While mapping between the two versions (a process called liftover)
is possible, this is a tedious process which we have not yet seen the need for as our users
are currently still relying on GRCh37. Therefore, we decided to stick with GRCh37
for MutationDistiller’s first version. However, we are well aware that in the future, the
demand for tools compatible with GRCh38 might increase. We are thus planning to add
this genome version to MutationDistiller as demand arises.
8.5.3 WGS data
In theory, MutationDistiller would be capable of addressing WGS projects already. How-
ever, MutationTaster can only handle a small part of WGS projects as it is limited to
protein-coding genes (but analyses non-coding variants contained in these). When start-
ing the project, WGS analysis was still prohibitively expensive and therefore not used
in routine clinical research, leading to a lack of data sources. We have thus decided to
limit MutationDistiller to WES projects and to use MutationTaster as the variant effect
predictor. In the course of the project, however, both of these points have changed –
thanks to the efforts of the ENCODE consortium and other projects, data on non-coding
regions and their regulatory relevance are readily available, while lower sequencing costs
have led to an increase in WGS usage [32].
In light of these developments, we are aware that the need for programs like Muta-
tionDistiller to cope with WGS data is rising steadily. In our research group, we have
since developed RegulationSpotter [142], a tool to analyse WGS projects in order to find
alterations located in areas of regulatory relevance. Moreover, RegulationSpotter is able
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to take HPO terms as input to identify variants located in regulatory regions of genes
that are connected with a given phenotype. However, the prediction quality for variants
located outside of transcript regions is currently not sufficient for direct incorporation
into clinical tools: with a mean of 3 million variants per WGS experiment, the tools
simply drown in false positives. With an increased use of WGS, this might change as
more training data becomes available, i.e. experimentally confirmed disease mutations
outside of protein-coding genes. We therefore decided to keep the two tools separate for
now. We are, however, considering to merge MutationDistiller and RegulationSpotter in
the future to develop software that is capable of both analysing WGS data and coping
with the variety of input options currently offered by MutationDistiller.
8.5.4 Mitochondrial DNA
In contrast to many other tools, MutationDistiller can detect mutations located in mi-
tochondrial DNA (mtDNA). However, as the software is based on diploidy, the program
cannot take heteroplasmy into account. As described in section 1.3.3, in many mitochon-
drial disorders, the degree of heteroplasmy plays a role and only individuals carrying a
high amount of mutated mtDNA will be affected by a disease.
To achieve this, we would have to read the degree of heteroplasmy from the VCF and
incorporate mitochondrial databases into MutationDistiller. Moreover, we would have to
alter our database structure accordingly and change the filters for external databases and
trios. While these changes are feasible, they require substantial changes to our database,
the integrated data, and how we call the data within MutationDistiller. We are therefore
planning to achieve this in a second version of the program.
8.5.5 gnomAD
We have currently implemented the variant database ExAC into MutationDistiller. As
described in section 2.2.3.2, this source contains human exome sequencing data from over
60,000 individuals. During the course of the development of MutationDistiller, gnomAD
[43], a genome-wide version, has been established. GnomAD contains over 125,000 exome
sequences and over 15,000 whole-genome sequences. These data were obtained from a
range of studies, both on diseases and on healthy populations. Previously, inclusion crite-
ria into gnomAD were unclear and did not allow to distinguish easily between sequences
from healthy individuals or patients suffering from genetic disorders. This has prevented
us from incorporating gnomAD data into MutationDistiller. However, this issue was
solve recently as gnomAD now separates the data into control and patient populations.
Therefore, we are currently working on adding gnomAD to MutationDistiller.
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8.5.6 Classification bins
MutationDistiller currently outputs an ordered list of genes and variants, sorted by how
well they match the user-defined criteria. However, depending on these criteria, a number
of genes and variants may receive the same score and are hence allocated to the same
rank. This is the case especially when users do not provide a wide range of criteria or
apply only few restrictions. For reasons of simplicity and to keep run-times fast, we
are currently displaying those variants in no particular order. In the future, we wish
to completely overhaul the ranking system and instead sort variants into bins indicating
how relevant they are for the given case. In this system, we would be able to not only take
the phenotypic relevance of a variant into account but to also sort alterations by their
predicted effect on the protein (e.g. missense alteration vs. NMD). Rather than ranking
the candidate variants, we would provide several bins of alterations that are deleterious,
while at the same time matching the phenotype of interest to varying degrees, expressed
by variant flags. Users could then toggle several switches depending on their focus to
show the predicted phenotype, effect, location, or gene function. For instance, one flag
would be whether the gene matches the phenotype description (in three stages, e.g.
green/yellow/red), another flag would denote the predicted effect (ClinVar/NMD/splice
site etc.), and another flag would be reserved for the moe of inheritance. Moreover,
additional flags could be added in later stages of the program, thus allowing for great
flexibility.
We have thus far decided not to implement this system yet for two main reasons. First,
all other variant prioritisation tools use ranked list in one way or another – hence users
are well acquainted with this approach. Rather than pushing users to learn how to use a
new program and a new sorting system at the same time, we decided to take one step at
a time. Moreover, we were still suffering from a lack of training data in order to generate
reliable thresholds for the binning system. However, with the increased usage of NGS
data in routine clinical settings, we are convinced that this problem is just a matter of
time. We are thus optimistic to be able to update MutationDistiller to a binning system
in the near future.
8.5.7 Data management
8.5.7.1 User data sustainability
In the development process of MutationDistiller, we have opted against an automated
process for removing data. Thus, we are currently manually running a script to delete
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user data at regular intervals. Now that the testing and development phase is over, we
are planning to automate this process. In addition to our deletion of user data in regular
intervals, and to provide further data security, users can currently simply delete their
projects by project ID and security code.
8.5.7.2 Data sources
We have not yet implemented an automated way of updating the data sources integrated
into MutationDistiller. Instead, we update data sets manually when we become aware
of relevant changes, which can be cumbersome: With GeneDistiller, MutationDistiller’s
parent tool that has been running for over 10 years now, we have experienced updates to
be complex and time consuming. However, an automated update protocol would make
our lives simpler while at the same time ensuring more up-to-date data. This would
be especially beneficial for data sources that we always want to keep as up-to-date as
possible (such as OMIM or HPO).
However, automated updates are not practical, necessary or feasible for all the different
data types MutationDistiller is using, since data structures can change and services be
discontinued. We are therefore planning to automate updates for selected data sources
that provide easy access to their data and do not alter data structure from one update
to the next. Current candidates for automatic updates are PanelApp, the HPO and
WikiPathways, but this list can be changed and broadened in the future.
8.6 Clinical use
Thanks to technical advances, the field of genomics has been catapulted into the digital
age. NGS methods allow for easy, fast and cheap sequencing, thus enabling work on
projects and cases that could not be handled before. However, the vast amounts of data
generated in NGS projects pose major obstacles and thus prevent clinicians, researchers
and genetic counsellors from attempting such endeavours [70, 143, 144]. With Muta-
tionDistiller, we have attempted to respond to the need for dedicated expert software
that is easy to use, provides a convenient user interface, and allows the analysis of large
data sets without having to obtain a bioinformatics degree first. MutationDistiller has
been designed as a tool to support rare disease research as well as clinical assessments.
However, it is not and cannot be a diagnostic tool or a medical device, since to achieve
this status strict regulations have to be followed, which are beyond the scope of this
research group.
Nevertheless, the tool has already entered the clinic: To date, over 14,000 individual cases
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have been uploaded to our database by clinicians and researchers. In recent months, Mu-
tationDistiller has seen over 1,000 cases every 30 days. The tool has been used in projects
from all around the world, and we expect this to increase still as clinicians more routinely
sequence their patients. We therefore hope that the work presented in this thesis can
bring some contributions to the field of genomics, and be of benefit for the numerous
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A Appendix – HPO optimisation weights
The following table displays summaries for all weight combinations ordered by lowest
number of unsolved cases. The abbreviation indicate as follows: anc_weight: weight
assigned to ancestor matches. desc_weight: weight assigned to descendant matches. n:
number of cases in total. first: number of indicated genes ranked on rank 1. one_five:
number of indicated genes ranked on ranks 1-5, respectively. gr_ten: number of in-
dicated genes ranked higher than rank 10. mean_rank: mean rank allocated to the
indicated genes for the given combination. not_found: number of cases ranked higher
than 100. Combination 210, marked with an asterisk, is currently implemented into
MutationDistiller.
combination ID direct_weight anc_weight desc_weight first one_five gr_ten mean_rank not_found
145 1.00 2.00 0.50 7 74 37 9.55 42
31 0.20 0.50 0.10 6 65 38 10.10 42
38 0.20 1.00 0.10 3 49 48 11.46 42
45 0.20 2.00 0.10 3 46 52 11.92 42
*210 5.00 0.05 2.00 70 108 26 5.82 43
224 5.00 0.20 2.00 70 109 26 5.86 43
217 5.00 0.10 2.00 70 108 26 5.87 43
160 2.00 0.05 1.00 67 108 26 5.96 43
60 0.50 0.05 0.20 70 107 24 5.99 43
231 5.00 0.50 2.00 70 107 24 5.99 43
110 1.00 0.05 0.50 67 108 26 6.02 43
167 2.00 0.10 1.00 67 108 26 6.02 43
117 1.00 0.10 0.50 67 107 26 6.12 43
174 2.00 0.20 1.00 67 107 26 6.12 43
67 0.50 0.10 0.20 69 106 24 6.17 43
238 5.00 1.00 2.00 69 106 24 6.17 43
124 1.00 0.20 0.50 66 106 25 6.25 43
111 1.00 0.05 1.00 56 104 27 6.28 43
168 2.00 0.10 2.00 56 104 27 6.28 43
10 0.20 0.05 0.10 66 105 25 6.28 43
181 2.00 0.50 1.00 66 105 25 6.28 43
161 2.00 0.05 2.00 56 103 28 6.30 43
61 0.50 0.05 0.50 56 105 27 6.37 43
118 1.00 0.10 1.00 56 105 27 6.37 43
175 2.00 0.20 2.00 56 105 27 6.37 43
11 0.20 0.05 0.20 56 104 27 6.52 43
68 0.50 0.10 0.50 56 103 28 6.52 43
125 1.00 0.20 1.00 56 103 28 6.52 43
182 2.00 0.50 2.00 56 104 27 6.52 43
17 0.20 0.10 0.10 61 99 25 6.64 43
131 1.00 0.50 0.50 61 99 25 6.64 43
188 2.00 1.00 1.00 61 99 25 6.64 43
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combination ID direct_weight anc_weight desc_weight first one_five gr_ten mean_rank not_found
75 0.50 0.20 0.50 55 101 26 6.66 43
112 1.00 0.05 2.00 42 102 27 6.83 43
18 0.20 0.10 0.20 55 98 27 6.84 43
132 1.00 0.50 1.00 55 98 27 6.84 43
189 2.00 1.00 2.00 55 98 27 6.84 43
62 0.50 0.05 1.00 42 100 28 6.87 43
119 1.00 0.10 2.00 42 100 28 6.87 43
24 0.20 0.20 0.10 39 90 27 7.43 43
138 1.00 1.00 0.50 39 90 27 7.43 43
195 2.00 2.00 1.00 39 90 27 7.43 43
25 0.20 0.20 0.20 37 90 28 7.60 43
82 0.50 0.50 0.50 37 90 28 7.60 43
139 1.00 1.00 1.00 37 90 28 7.60 43
196 2.00 2.00 2.00 37 90 28 7.60 43
63 0.50 0.05 2.00 37 88 28 7.63 43
89 0.50 1.00 0.50 8 69 32 8.99 43
146 1.00 2.00 1.00 8 69 32 8.99 43
88 0.50 1.00 0.20 8 75 36 9.12 43
90 0.50 1.00 1.00 11 67 35 9.15 43
147 1.00 2.00 2.00 11 67 35 9.15 43
87 0.50 1.00 0.10 8 75 38 9.22 43
144 1.00 2.00 0.20 8 75 38 9.22 43
142 1.00 2.00 0.05 8 74 37 9.28 43
86 0.50 1.00 0.05 8 74 38 9.28 43
143 1.00 2.00 0.10 8 74 38 9.28 43
32 0.20 0.50 0.20 6 60 34 9.59 43
91 0.50 1.00 2.00 14 62 39 9.60 43
33 0.20 0.50 0.50 9 57 38 9.68 43
30 0.20 0.50 0.05 6 66 39 9.77 43
34 0.20 0.50 1.00 13 53 43 10.10 43
35 0.20 0.50 2.00 15 54 42 10.23 43
93 0.50 2.00 0.05 3 51 45 10.72 43
94 0.50 2.00 0.10 3 51 46 10.73 43
97 0.50 2.00 1.00 3 46 47 10.74 43
95 0.50 2.00 0.20 3 51 44 10.75 43
96 0.50 2.00 0.50 3 47 44 10.77 43
98 0.50 2.00 2.00 8 45 52 10.85 43
37 0.20 1.00 0.05 3 50 47 10.99 43
39 0.20 1.00 0.20 3 45 47 11.05 43
40 0.20 1.00 0.50 3 44 54 11.18 43
41 0.20 1.00 1.00 7 42 55 11.20 43
42 0.20 1.00 2.00 12 42 55 11.21 43
44 0.20 2.00 0.05 3 47 50 11.46 43
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combination ID direct_weight anc_weight desc_weight first one_five gr_ten mean_rank not_found
46 0.20 2.00 0.20 3 42 52 11.50 43
49 0.20 2.00 2.00 6 38 60 11.70 43
47 0.20 2.00 0.50 3 40 57 11.74 43
48 0.20 2.00 1.00 3 41 61 12.06 43
159 2.00 0.05 0.50 69 110 23 5.45 44
209 5.00 0.05 1.00 69 108 23 5.45 44
216 5.00 0.10 1.00 69 108 23 5.46 44
208 5.00 0.05 0.50 65 106 24 5.50 44
223 5.00 0.20 1.00 69 107 23 5.51 44
109 1.00 0.05 0.20 69 107 23 5.51 44
166 2.00 0.10 0.50 69 108 23 5.52 44
207 5.00 0.05 0.20 63 106 24 5.54 44
158 2.00 0.05 0.20 65 106 24 5.55 44
215 5.00 0.10 0.50 65 106 24 5.55 44
222 5.00 0.20 0.50 64 106 25 5.58 44
173 2.00 0.20 0.50 68 108 24 5.58 44
214 5.00 0.10 0.20 62 106 25 5.60 44
157 2.00 0.05 0.10 63 106 25 5.61 44
108 1.00 0.05 0.10 64 106 25 5.61 44
165 2.00 0.10 0.20 64 106 25 5.61 44
107 1.00 0.05 0.05 62 104 24 5.62 44
164 2.00 0.10 0.10 62 104 24 5.62 44
206 5.00 0.05 0.10 62 106 25 5.62 44
221 5.00 0.20 0.20 61 104 24 5.65 44
156 2.00 0.05 0.05 61 104 24 5.65 44
220 5.00 0.20 0.10 61 102 24 5.65 44
59 0.50 0.05 0.10 66 107 25 5.65 44
116 1.00 0.10 0.20 66 107 25 5.65 44
230 5.00 0.50 1.00 66 107 25 5.65 44
213 5.00 0.10 0.10 61 104 24 5.67 44
163 2.00 0.10 0.05 61 102 24 5.68 44
205 5.00 0.05 0.05 61 104 24 5.69 44
58 0.50 0.05 0.05 63 103 25 5.69 44
115 1.00 0.10 0.10 63 103 25 5.69 44
172 2.00 0.20 0.20 63 103 25 5.69 44
229 5.00 0.50 0.50 63 103 25 5.69 44
212 5.00 0.10 0.05 61 103 24 5.70 44
219 5.00 0.20 0.05 61 102 23 5.71 44
114 1.00 0.10 0.05 62 102 25 5.73 44
171 2.00 0.20 0.10 62 102 25 5.73 44
228 5.00 0.50 0.20 62 102 24 5.74 44
227 5.00 0.50 0.10 62 102 24 5.76 44
170 2.00 0.20 0.05 62 102 24 5.77 44
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combination ID direct_weight anc_weight desc_weight first one_five gr_ten mean_rank not_found
65 0.50 0.10 0.05 64 102 24 5.78 44
122 1.00 0.20 0.10 64 102 24 5.78 44
236 5.00 1.00 0.50 64 102 24 5.78 44
235 5.00 1.00 0.20 64 103 24 5.81 44
66 0.50 0.10 0.10 65 103 23 5.81 44
123 1.00 0.20 0.20 65 103 23 5.81 44
178 2.00 0.50 0.10 65 103 22 5.81 44
237 5.00 1.00 1.00 65 103 23 5.81 44
226 5.00 0.50 0.05 61 102 24 5.81 44
121 1.00 0.20 0.05 64 102 24 5.82 44
179 2.00 0.50 0.20 65 103 22 5.82 44
9 0.20 0.05 0.05 66 104 23 5.84 44
180 2.00 0.50 0.50 66 104 23 5.84 44
177 2.00 0.50 0.05 65 103 22 5.85 44
234 5.00 1.00 0.10 64 103 24 5.86 44
233 5.00 1.00 0.05 64 103 25 5.88 44
72 0.50 0.20 0.05 63 99 22 6.03 44
243 5.00 2.00 0.50 63 99 22 6.03 44
74 0.50 0.20 0.20 64 100 23 6.04 44
245 5.00 2.00 2.00 64 100 23 6.04 44
73 0.50 0.20 0.10 63 99 23 6.05 44
244 5.00 2.00 1.00 63 99 23 6.05 44
242 5.00 2.00 0.20 63 99 24 6.10 44
16 0.20 0.10 0.05 61 99 23 6.12 44
187 2.00 1.00 0.50 61 99 23 6.12 44
241 5.00 2.00 0.10 63 99 24 6.15 44
240 5.00 2.00 0.05 63 99 24 6.15 44
130 1.00 0.50 0.20 61 99 23 6.18 44
129 1.00 0.50 0.10 61 100 25 6.23 44
186 2.00 1.00 0.20 61 100 25 6.23 44
128 1.00 0.50 0.05 61 100 25 6.24 44
185 2.00 1.00 0.10 61 100 25 6.24 44
184 2.00 1.00 0.05 61 100 26 6.29 44
69 0.50 0.10 1.00 42 99 27 6.40 44
126 1.00 0.20 2.00 42 99 27 6.40 44
76 0.50 0.20 1.00 41 98 26 6.53 44
133 1.00 0.50 2.00 41 96 25 6.58 44
12 0.20 0.05 0.50 41 96 27 6.63 44
19 0.20 0.10 0.50 41 93 26 6.89 44
81 0.50 0.50 0.20 39 93 27 7.03 44
23 0.20 0.20 0.05 39 94 28 7.06 44
194 2.00 2.00 0.50 39 94 28 7.06 44
80 0.50 0.50 0.10 39 92 28 7.07 44
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combination ID direct_weight anc_weight desc_weight first one_five gr_ten mean_rank not_found
137 1.00 1.00 0.20 39 92 28 7.07 44
79 0.50 0.50 0.05 38 92 30 7.08 44
136 1.00 1.00 0.10 38 92 30 7.08 44
193 2.00 2.00 0.20 38 92 30 7.08 44
135 1.00 1.00 0.05 36 92 30 7.15 44
192 2.00 2.00 0.10 36 92 30 7.15 44
70 0.50 0.10 2.00 37 87 27 7.17 44
77 0.50 0.20 2.00 38 87 26 7.22 44
191 2.00 2.00 0.05 35 92 30 7.23 44
83 0.50 0.50 1.00 31 82 28 7.30 44
140 1.00 1.00 2.00 31 82 28 7.30 44
13 0.20 0.05 1.00 35 85 29 7.35 44
20 0.20 0.10 1.00 36 83 26 7.48 44
26 0.20 0.20 0.50 30 76 28 7.53 44
14 0.20 0.05 2.00 34 80 31 7.60 44
21 0.20 0.10 2.00 34 78 29 7.76 44
84 0.50 0.50 2.00 29 72 30 7.94 44
27 0.20 0.20 1.00 28 70 30 8.12 44
28 0.20 0.20 2.00 26 69 32 8.33 44
85 0.50 1.00 0.00 8 74 29 8.15 48
141 1.00 2.00 0.00 8 74 29 8.15 48
29 0.20 0.50 0.00 6 66 31 8.64 48
92 0.50 2.00 0.00 3 52 36 9.47 48
36 0.20 1.00 0.00 3 51 37 9.70 48
43 0.20 2.00 0.00 3 48 40 10.00 48
211 5.00 0.10 0.00 61 104 14 4.49 49
204 5.00 0.05 0.00 61 104 15 4.50 49
218 5.00 0.20 0.00 61 103 14 4.50 49
106 1.00 0.05 0.00 61 103 14 4.50 49
155 2.00 0.05 0.00 61 103 14 4.50 49
162 2.00 0.10 0.00 61 103 14 4.50 49
57 0.50 0.05 0.00 61 103 15 4.58 49
113 1.00 0.10 0.00 61 103 15 4.58 49
169 2.00 0.20 0.00 61 103 15 4.58 49
225 5.00 0.50 0.00 61 103 15 4.58 49
64 0.50 0.10 0.00 64 104 17 4.66 49
120 1.00 0.20 0.00 64 104 17 4.66 49
232 5.00 1.00 0.00 64 104 17 4.66 49
8 0.20 0.05 0.00 65 104 16 4.66 49
176 2.00 0.50 0.00 65 104 16 4.66 49
71 0.50 0.20 0.00 63 99 18 4.93 49
239 5.00 2.00 0.00 63 99 18 4.93 49
15 0.20 0.10 0.00 61 100 20 5.09 49
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combination ID direct_weight anc_weight desc_weight first one_five gr_ten mean_rank not_found
127 1.00 0.50 0.00 61 100 20 5.09 49
183 2.00 1.00 0.00 61 100 20 5.09 49
22 0.20 0.20 0.00 35 92 23 6.04 49
78 0.50 0.50 0.00 35 92 23 6.04 49
134 1.00 1.00 0.00 35 92 23 6.04 49
190 2.00 2.00 0.00 35 92 23 6.04 49
53 0.50 0.00 0.20 74 105 19 4.78 53
203 5.00 0.00 2.00 74 105 19 4.78 53
3 0.20 0.00 0.10 71 106 20 4.93 53
103 1.00 0.00 0.50 71 106 20 4.93 53
153 2.00 0.00 1.00 71 106 20 4.93 53
4 0.20 0.00 0.20 58 103 23 5.36 53
54 0.50 0.00 0.50 58 103 23 5.36 53
104 1.00 0.00 1.00 58 103 23 5.36 53
154 2.00 0.00 2.00 58 103 23 5.36 53
55 0.50 0.00 1.00 43 100 21 5.91 53
105 1.00 0.00 2.00 43 100 21 5.91 53
5 0.20 0.00 0.50 42 96 23 6.17 53
56 0.50 0.00 2.00 38 92 23 6.61 53
6 0.20 0.00 1.00 36 90 24 6.81 53
7 0.20 0.00 2.00 35 86 25 7.03 53
52 0.50 0.00 0.10 73 105 16 4.29 54
102 1.00 0.00 0.20 73 105 16 4.29 54
202 5.00 0.00 1.00 73 105 16 4.29 54
100 1.00 0.00 0.05 68 104 16 4.31 54
150 2.00 0.00 0.10 68 104 16 4.31 54
51 0.50 0.00 0.05 70 104 16 4.31 54
101 1.00 0.00 0.10 70 104 16 4.31 54
151 2.00 0.00 0.20 70 104 16 4.31 54
201 5.00 0.00 0.50 70 104 16 4.31 54
200 5.00 0.00 0.20 67 104 16 4.31 54
2 0.20 0.00 0.05 73 106 16 4.31 54
152 2.00 0.00 0.50 73 106 16 4.31 54
199 5.00 0.00 0.10 67 104 16 4.33 54
149 2.00 0.00 0.05 67 104 16 4.34 54
198 5.00 0.00 0.05 67 103 16 4.35 54
1 0.20 0.00 0.00 65 104 6 3.02 63
50 0.50 0.00 0.00 65 104 6 3.02 63
99 1.00 0.00 0.00 65 104 6 3.02 63
148 2.00 0.00 0.00 65 104 6 3.02 63
197 5.00 0.00 0.00 65 104 6 3.02 63
Appendix 104
B Appendix – Expression tissue groups
This table provides a summary of the the groups and subgroups developed to structure expression data downloaded from Ex-
pressionAtlas.
datasource class group sub-tissues
E-MTAB-4344 organs brain brain
E-MTAB-4344 organs kidney kidney
E-MTAB-4344 organs liver liver
E-MTAB-4344 organs lung lung
E-MTAB-4344 organs heart heart
E-MTAB-4344 organs gastrointestinal tract sigmoid colon
E-MTAB-4344 organs gastrointestinal tract small intestine
E-MTAB-4344 organs reproductive organs ovary
E-MTAB-4344 organs reproductive organs testis
E-MTAB-4344 tissues adipose tissue adipose tissue
E-MTAB-4344 systems nervous system brain
E-MTAB-4344 systems circulatory/respiratory system heart
E-MTAB-4344 systems circulatory/respiratory system lung
E-MTAB-4344 systems immune system spleen
E-MTAB-4344 systems reproductive system ovary
E-MTAB-4344 systems reproductive system testis
E-MTAB-4344 systems food intake/digestion sigmoid colon
E-MTAB-4344 systems food intake/digestion small intestine
E-MTAB-4344 systems urinary system kidney
E-MTAB-4344 systems endocrine system adrenal gland
E-MTAB-4344 systems endocrine system pancreas
E-MTAB-3358 organs brain amygdala
E-MTAB-3358 organs brain brain
E-MTAB-3358 organs brain caudate nucleus
E-MTAB-3358 organs brain cerebellum
E-MTAB-3358 organs brain cerebral meninges
E-MTAB-3358 organs brain diencephalon
E-MTAB-3358 organs brain dura mater
E-MTAB-3358 organs brain globus pallidus
E-MTAB-3358 organs brain hippocampus
E-MTAB-3358 organs brain locus coeruleus
E-MTAB-3358 organs brain medulla oblongata
E-MTAB-3358 organs brain middle frontal gyrus
E-MTAB-3358 organs brain middle temporal gyrus
E-MTAB-3358 organs brain occipital cortex
E-MTAB-3358 organs brain occipital lobe
E-MTAB-3358 organs brain parietal lobe
E-MTAB-3358 organs brain putamen
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datasource class group sub-tissues
E-MTAB-3358 organs brain substantia nigra
E-MTAB-3358 organs brain thalamus
E-MTAB-3358 organs gastrointestinal tract appendix
E-MTAB-3358 organs gastrointestinal tract colon
E-MTAB-3358 organs heart artery
E-MTAB-3358 organs heart heart
E-MTAB-3358 organs heart left atrium
E-MTAB-3358 organs heart left ventricle
E-MTAB-3358 organs heart mitral valve
E-MTAB-3358 organs heart pulmonary valve
E-MTAB-3358 organs heart tricuspid valve
E-MTAB-3358 organs kidney kidney
E-MTAB-3358 organs lung lung
E-MTAB-3358 organs reproductive organs cervix
E-MTAB-3358 organs reproductive organs epididymis
E-MTAB-3358 organs reproductive organs ovary
E-MTAB-3358 organs reproductive organs penis
E-MTAB-3358 organs reproductive organs placenta
E-MTAB-3358 organs reproductive organs prostate
E-MTAB-3358 organs reproductive organs seminal vesicle
E-MTAB-3358 organs reproductive organs testis
E-MTAB-3358 organs reproductive organs uterus
E-MTAB-3358 organs reproductive organs vagina
E-MTAB-3358 organs reproductive organs vas deferens
E-MTAB-3358 organs skin skin
E-MTAB-3358 organs gallbladder gallbladder
E-MTAB-3358 organs olfactory apparatus olfactory apparatus
E-MTAB-3358 systems circulatory/respiratory system artery
E-MTAB-3358 systems circulatory/respiratory system heart
E-MTAB-3358 systems circulatory/respiratory system left atrium
E-MTAB-3358 systems circulatory/respiratory system left ventricle
E-MTAB-3358 systems circulatory/respiratory system lung
E-MTAB-3358 systems circulatory/respiratory system mitral valve
E-MTAB-3358 systems circulatory/respiratory system pulmonary valve
E-MTAB-3358 systems circulatory/respiratory system tricuspid valve
E-MTAB-3358 systems endocrine system pancreas
E-MTAB-3358 systems endocrine system pineal gland
E-MTAB-3358 systems endocrine system pituitary gland
E-MTAB-3358 systems food intake/digestion appendix
E-MTAB-3358 systems food intake/digestion colon
E-MTAB-3358 systems food intake/digestion parotid gland
E-MTAB-3358 systems food intake/digestion submandibular gland
E-MTAB-3358 systems food intake/digestion tongue
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datasource class group sub-tissues
E-MTAB-3358 systems immune system lymph node
E-MTAB-3358 systems immune system spleen
E-MTAB-3358 systems nervous system amygdala
E-MTAB-3358 systems nervous system brain
E-MTAB-3358 systems nervous system caudate nucleus
E-MTAB-3358 systems nervous system cerebellum
E-MTAB-3358 systems nervous system cerebral meninges
E-MTAB-3358 systems nervous system diencephalon
E-MTAB-3358 systems nervous system dura mater
E-MTAB-3358 systems nervous system globus pallidus
E-MTAB-3358 systems nervous system hippocampus
E-MTAB-3358 systems nervous system locus coeruleus
E-MTAB-3358 systems nervous system medulla oblongata
E-MTAB-3358 systems nervous system middle frontal gyrus
E-MTAB-3358 systems nervous system middle temporal gyrus
E-MTAB-3358 systems nervous system occipital cortex
E-MTAB-3358 systems nervous system occipital lobe
E-MTAB-3358 systems nervous system parietal lobe
E-MTAB-3358 systems nervous system putamen
E-MTAB-3358 systems nervous system spinal cord
E-MTAB-3358 systems nervous system substantia nigra
E-MTAB-3358 systems nervous system thalamus
E-MTAB-3358 systems neuromuscular smooth muscle
E-MTAB-3358 systems reproductive system cervix
E-MTAB-3358 systems reproductive system epididymis
E-MTAB-3358 systems reproductive system ovary
E-MTAB-3358 systems reproductive system penis
E-MTAB-3358 systems reproductive system placenta
E-MTAB-3358 systems reproductive system prostate
E-MTAB-3358 systems reproductive system seminal vesicle
E-MTAB-3358 systems reproductive system testis
E-MTAB-3358 systems reproductive system uterus
E-MTAB-3358 systems reproductive system vagina
E-MTAB-3358 systems reproductive system vas deferens
E-MTAB-3358 systems skin skin
E-MTAB-3358 systems urinary system kidney
E-MTAB-3358 tissues bone marrow bone marrow
E-MTAB-3358 tissues mammary tissue breast
E-MTAB-3358 tissues skin skin
E-MTAB-3358 tissues smooth muscle smooth muscle
E-MTAB-5214 organs brain amygdala
E-MTAB-5214 organs brain anterior cingulate cortex (BA24)
E-MTAB-5214 organs brain caudate (basal ganglia)
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datasource class group sub-tissues
E-MTAB-5214 organs brain cerebellar hemisphere
E-MTAB-5214 organs brain cerebellum
E-MTAB-5214 organs brain cerebral cortex
E-MTAB-5214 organs brain frontal cortex
E-MTAB-5214 organs brain hippocampus
E-MTAB-5214 organs brain hypothalamus
E-MTAB-5214 organs brain nucleus accumbens (basal ganglia)
E-MTAB-5214 organs brain putamen (basal ganglia)
E-MTAB-5214 organs brain substantia nigra
E-MTAB-5214 organs gastrointestinal tract esophagus muscularis mucosa
E-MTAB-5214 organs gastrointestinal tract gastroesophageal junction
E-MTAB-5214 organs gastrointestinal tract mucosa of esophagus
E-MTAB-5214 organs gastrointestinal tract sigmoid colon
E-MTAB-5214 organs gastrointestinal tract stomach
E-MTAB-5214 organs gastrointestinal tract terminal ileum of small intestine
E-MTAB-5214 organs gastrointestinal tract transverse colon
E-MTAB-5214 organs heart aorta
E-MTAB-5214 organs heart coronary artery
E-MTAB-5214 organs heart left ventricle
E-MTAB-5214 organs kidney cortex of kidney
E-MTAB-5214 organs liver liver
E-MTAB-5214 organs lung lung
E-MTAB-5214 organs reproductive organs cervix
E-MTAB-5214 organs reproductive organs fallopian tube
E-MTAB-5214 organs reproductive organs ovary
E-MTAB-5214 organs reproductive organs prostate
E-MTAB-5214 organs reproductive organs testis
E-MTAB-5214 organs reproductive organs uterus
E-MTAB-5214 organs reproductive organs vagina
E-MTAB-5214 organs skin skin of lower leg
E-MTAB-5214 organs skin skin of suprapubic region
E-MTAB-5214 systems circulatory/respiratory system aorta
E-MTAB-5214 systems circulatory/respiratory system atrial appendage of heart
E-MTAB-5214 systems circulatory/respiratory system coronary artery
E-MTAB-5214 systems circulatory/respiratory system left ventricle
E-MTAB-5214 systems circulatory/respiratory system lung
E-MTAB-5214 systems circulatory/respiratory system tibial artery
E-MTAB-5214 systems circulatory/respiratory system whole blood
E-MTAB-5214 systems endocrine system adrenal gland
E-MTAB-5214 systems endocrine system pancreas
E-MTAB-5214 systems endocrine system pituitary gland
E-MTAB-5214 systems endocrine system thyroid
E-MTAB-5214 systems food intake/digestion esophagus muscularis mucosa
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datasource class group sub-tissues
E-MTAB-5214 systems food intake/digestion gastroesophageal junction
E-MTAB-5214 systems food intake/digestion minor salivary gland
E-MTAB-5214 systems food intake/digestion mucosa of esophagus
E-MTAB-5214 systems food intake/digestion sigmoid colon
E-MTAB-5214 systems food intake/digestion stomach
E-MTAB-5214 systems food intake/digestion terminal ileum of small intestine
E-MTAB-5214 systems food intake/digestion transverse colon
E-MTAB-5214 systems immune system spleen
E-MTAB-5214 systems nervous system amygdala
E-MTAB-5214 systems nervous system anterior cingulate cortex (BA24)
E-MTAB-5214 systems nervous system caudate (basal ganglia)
E-MTAB-5214 systems nervous system cerebellar hemisphere
E-MTAB-5214 systems nervous system cerebellum
E-MTAB-5214 systems nervous system cerebral cortex
E-MTAB-5214 systems nervous system frontal cortex
E-MTAB-5214 systems nervous system hippocampus
E-MTAB-5214 systems nervous system hypothalamus
E-MTAB-5214 systems nervous system nucleus accumbens (basal ganglia)
E-MTAB-5214 systems nervous system putamen (basal ganglia)
E-MTAB-5214 systems nervous system spinal cord (cervical c-1)
E-MTAB-5214 systems nervous system substantia nigra
E-MTAB-5214 systems nervous system tibial nerve
E-MTAB-5214 systems neuromuscular skeletal muscle
E-MTAB-5214 systems reproductive system cervix
E-MTAB-5214 systems reproductive system fallopian tube
E-MTAB-5214 systems reproductive system ovary
E-MTAB-5214 systems reproductive system prostate
E-MTAB-5214 systems reproductive system testis
E-MTAB-5214 systems reproductive system uterus
E-MTAB-5214 systems reproductive system vagina
E-MTAB-5214 systems skin skin of lower leg
E-MTAB-5214 systems skin skin of suprapubic region
E-MTAB-5214 systems urinary system bladder
E-MTAB-5214 systems urinary system cortex of kidney
E-MTAB-5214 tissues adipose tissue subcutaneous adipose tissue
E-MTAB-5214 tissues adipose tissue visceral adipose tissue
E-MTAB-5214 tissues cellular EBV-transformed lymphocyte
E-MTAB-5214 tissues cellular leukemia cell line
E-MTAB-5214 tissues cellular transformed fibroblast
E-MTAB-5214 tissues cellular whole blood
E-MTAB-5214 tissues mammary tissue breast
E-MTAB-5214 tissues muscle skeletal muscle
E-MTAB-5214 tissues skin skin of lower leg
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datasource class group sub-tissues
E-MTAB-5214 tissues skin skin of suprapubic region
E-PROT-3,E-MTAB-2836 organs brain cerebral cortex
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract appendix
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract colon
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract duodenum
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract esophagus
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract rectum
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract small intestine
E-PROT-3,E-MTAB-2836 organs gastrointestinal tract stomach
E-PROT-3,E-MTAB-2836 organs heart heart
E-PROT-3,E-MTAB-2836 organs kidney kidney
E-PROT-3,E-MTAB-2836 organs liver liver
E-PROT-3,E-MTAB-2836 organs lung lung
E-PROT-3,E-MTAB-2836 organs reproductive organs endometrium
E-PROT-3,E-MTAB-2836 organs reproductive organs fallopian tube
E-PROT-3,E-MTAB-2836 organs reproductive organs ovary
E-PROT-3,E-MTAB-2836 organs reproductive organs placenta
E-PROT-3,E-MTAB-2836 organs reproductive organs prostate
E-PROT-3,E-MTAB-2836 organs reproductive organs testis
E-PROT-3,E-MTAB-2836 organs skin skin
E-PROT-3,E-MTAB-2836 organs gallbladder gallbladder
E-PROT-3,E-MTAB-2836 systems circulatory/respiratory system heart
E-PROT-3,E-MTAB-2836 systems circulatory/respiratory system lung
E-PROT-3,E-MTAB-2836 systems endocrine system adrenal gland
E-PROT-3,E-MTAB-2836 systems endocrine system pancreas
E-PROT-3,E-MTAB-2836 systems endocrine system thyroid
E-PROT-3,E-MTAB-2836 systems food intake/digestion appendix
E-PROT-3,E-MTAB-2836 systems food intake/digestion colon
E-PROT-3,E-MTAB-2836 systems food intake/digestion duodenum
E-PROT-3,E-MTAB-2836 systems food intake/digestion esophagus
E-PROT-3,E-MTAB-2836 systems food intake/digestion rectum
E-PROT-3,E-MTAB-2836 systems food intake/digestion salivary gland
E-PROT-3,E-MTAB-2836 systems food intake/digestion small intestine
E-PROT-3,E-MTAB-2836 systems food intake/digestion stomach
E-PROT-3,E-MTAB-2836 systems immune system lymph node
E-PROT-3,E-MTAB-2836 systems immune system spleen
E-PROT-3,E-MTAB-2836 systems immune system tonsil
E-PROT-3,E-MTAB-2836 systems nervous system cerebral cortex
E-PROT-3,E-MTAB-2836 systems neuromuscular skeletal muscle
E-PROT-3,E-MTAB-2836 systems neuromuscular smooth muscle
E-PROT-3,E-MTAB-2836 systems reproductive system endometrium
E-PROT-3,E-MTAB-2836 systems reproductive system fallopian tube
E-PROT-3,E-MTAB-2836 systems reproductive system ovary
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datasource class group sub-tissues
E-PROT-3,E-MTAB-2836 systems reproductive system placenta
E-PROT-3,E-MTAB-2836 systems reproductive system prostate
E-PROT-3,E-MTAB-2836 systems reproductive system testis
E-PROT-3,E-MTAB-2836 systems skin skin
E-PROT-3,E-MTAB-2836 systems urinary system bladder
E-PROT-3,E-MTAB-2836 systems urinary system kidney
E-PROT-3,E-MTAB-2836 tissues adipose tissue adipose tissue
E-PROT-3,E-MTAB-2836 tissues bone marrow bone marrow
E-PROT-3,E-MTAB-2836 tissues muscle skeletal muscle
E-PROT-3,E-MTAB-2836 tissues muscle smooth muscle
E-PROT-3,E-MTAB-2836 tissues skin skin
E-MTAB-513 organs brain brain
E-MTAB-513 organs gastrointestinal tract colon
E-MTAB-513 organs heart heart
E-MTAB-513 organs kidney kidney
E-MTAB-513 organs liver liver
E-MTAB-513 organs lung lung
E-MTAB-513 organs reproductive organs ovary
E-MTAB-513 organs reproductive organs prostate
E-MTAB-513 organs reproductive organs testis
E-MTAB-513 systems circulatory/respiratory system heart
E-MTAB-513 systems circulatory/respiratory system lung
E-MTAB-513 systems endocrine system adrenal gland
E-MTAB-513 systems endocrine system thyroid
E-MTAB-513 systems food/digestion colon
E-MTAB-513 systems immune system leukocyte
E-MTAB-513 systems immune system lymph node
E-MTAB-513 systems nervous system brain
E-MTAB-513 systems neuromuscular skeletal muscle
E-MTAB-513 systems reproductive system ovary
E-MTAB-513 systems reproductive system prostate
E-MTAB-513 systems reproductive system testis
E-MTAB-513 systems urinary system kidney
E-MTAB-513 tissues adipose tissue adipose tissue
E-MTAB-513 tissues cellular leukocyte
E-MTAB-513 tissues mammary tissue breast
E-MTAB-513 tissues muscle skeletal muscle
E-PROT-1 organs brain frontal cortex
E-PROT-1 organs gastrointestinal tract colon
E-PROT-1 organs gastrointestinal tract esophagus
E-PROT-1 organs gastrointestinal tract rectum
E-PROT-1 organs heart heart
E-PROT-1 organs kidney kidney
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datasource class group sub-tissues
E-PROT-1 organs liver liver
E-PROT-1 organs lung lung
E-PROT-1 organs reproductive organs ovary
E-PROT-1 organs reproductive organs prostate
E-PROT-1 organs reproductive organs testis
E-PROT-1 organs gallbladder gallbladder
E-PROT-1 systems circulatory/respiratory system heart
E-PROT-1 systems circulatory/respiratory system lung
E-PROT-1 systems circulatory/respiratory system platelet
E-PROT-1 systems endocrine system adrenal gland
E-PROT-1 systems endocrine system pancreas
E-PROT-1 systems food intake/digestion colon
E-PROT-1 systems food intake/digestion esophagus
E-PROT-1 systems food intake/digestion rectum
E-PROT-1 systems immune system B cell
E-PROT-1 systems immune system CD4-positive T cell
E-PROT-1 systems immune system CD8-positive T cell
E-PROT-1 systems immune system monocyte
E-PROT-1 systems immune system natural killer cell
E-PROT-1 systems nervous system frontal cortex
E-PROT-1 systems nervous system spinal cord
E-PROT-1 systems reproductive system ovary
E-PROT-1 systems reproductive system prostate
E-PROT-1 systems reproductive system testis
E-PROT-1 systems urinary system kidney
E-PROT-1 systems urinary system bladder
E-PROT-1 tissues cellular B cell
E-PROT-1 tissues cellular CD4-positive T cell
E-PROT-1 tissues cellular CD8-positive T cell
E-PROT-1 tissues cellular monocyte
E-PROT-1 tissues cellular natural killer cell
E-PROT-1 tissues cellular platelet
E-PROT-1 organs eye retina
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C Appendix – MutationDistiller database ERD
In this figure, I provide a comprehensive ERD of the tables and schemas used by MutationDistiller. Please note that this might
change with updates and new versions. Symbols indicate data types: 123 - numeric; ABC - text; tick - boolean; clock - date. A
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